US4912040A - Eucaryotic expression system - Google Patents

Eucaryotic expression system Download PDF

Info

Publication number
US4912040A
US4912040A US07/010,351 US1035187A US4912040A US 4912040 A US4912040 A US 4912040A US 1035187 A US1035187 A US 1035187A US 4912040 A US4912040 A US 4912040A
Authority
US
United States
Prior art keywords
bip
cell
host cell
grp78
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/010,351
Inventor
Randal J. Kaufman
Andrew Dorner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Priority to US07/010,351 priority Critical patent/US4912040A/en
Assigned to GENETICS INSTITUTE, INC. reassignment GENETICS INSTITUTE, INC. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: DORNER, ANDREW, KAUFMAN, RANDAL J.
Priority to JP63501181A priority patent/JPH01501363A/en
Priority to ES8703256A priority patent/ES2013324A6/en
Priority to PCT/US1987/002971 priority patent/WO1988003558A1/en
Priority to AU11002/88A priority patent/AU1100288A/en
Priority to DE88900621T priority patent/DE3789017D1/en
Priority to CA000551771A priority patent/CA1297436C/en
Priority to AT88900621T priority patent/ATE101195T1/en
Priority to EP88900621A priority patent/EP0289597B1/en
Priority to KR1019880700824A priority patent/KR890700164A/en
Publication of US4912040A publication Critical patent/US4912040A/en
Application granted granted Critical
Assigned to GENETICS INSTITUTE, LLC reassignment GENETICS INSTITUTE, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: GENETICS INSTITUTE, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6456Plasminogen activators
    • C12N9/6459Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21069Protein C activated (3.4.21.69)

Definitions

  • This invention relates to improvements in the expression and secretion of heterologous proteins from eucaryotic cells. Complete citations for references cited herein are set forth immediately preceding the claims.
  • the signal sequence is usually removed and a high mannose oligosaccharide core unit is transferred to a sparagine residues located in the sequence Asn-X-Ser/Thr where X can be any amino acid, except perhaps proline.
  • This N-linked core glycosylation occurs cotranslationally and it appears that the efficiency of glycosylation is dependent on the presentation of an appropriate conformation of the peptide chain as it enters the endoplasmic reticulum. Potential N-linked glycosylation sites may no longer be accessible after the protein has folded (Kornfeld & Kornfeld).
  • Proteins move from the endoplasmic reticulum to the Golgi apparatus where modifications such as sulfation and processing of the high mannose oligosaccharide chain to a complex type occurs and the proteins are directed to their proper destinations (Dunphy & Rothman Cell 1985).
  • the movement from the ER to the Golgi has been identified as the rate limiting step in intracellular transport (Lodish et al. Nature 1983; Fitting & Kabat JBC 1982 J. Cell Biol 1985). Few proteins resident in the ER have been extensively studied for their interaction with secretory proteins transiting that compartment.
  • hsp70 is the most abundant of these induced proteins. Proteins related to hsp70 are found in unstressed mammalian cells. There are three main members of the mammalian hsp70-like group of proteins: hsp70, hsc70, and GRP78 (Pelham Cell 1986) Following heat shock, synthesis of hsp70 is induced and the protein migrates to the nucleus where it is found in tight association with nucleoli. hsp70 can be released from this association by the addition of ATP in vitro.
  • hsp70 disaggregates heat damaged proteins by an ATP dependent mechanism to facilitate recovery from heat shock (Lewis & Pelham EMBO J 1985).
  • hsc70 is found at high basal levels in growing cells and is only slightly heat inducible (Pelham Cell 1986).
  • hsc70 has recently been identified as "uncoating ATPase", a constitively expressed enzyme that releases clathrin triskelions from coated vesicles in an ATP dependent reaction (Chappell et al Cell 1986, Ungewickell EMBO J 1985).
  • GRP78 was initially reported to be one of two proteins whose synthesis was induced by glucose starvation in chick fibroblasts (Shiu et al Proc. Natl. Acad. Sci. U.S.A. Its synthesis can also be induced by inhibitors of N-linked glycosylation such as tunicamycin, glucosamine or 2-deoxyglucose (Olden et al Proc. Natl. Acad. Sci. U.S.A 1979, Pouyssegur et al Cell 1977). GRP78 is not heat inducible and its basal level is high in secreting cells.
  • BiP/GRP78 immunoglobulin heavy chain binding protein
  • BiP/GRP78 may associate in secreting cells with underglycosylated or improperly folded proteins in the endoplasmic reticulum and help clear them in analogy to the hypothesized role of hsp70 in the nucleus (Pelham Cell 1986). Such a function is consistent with the induction of increased levels of GRP78 synthesis under conditions which disrupt N-linked glycosylation. Recent studies on abberant proteins which fail to transit out of the ER have been interpreted to show that BiP binds to them in the ER although the identity of grp78 and BiP was disputed (Gething et al Cell 1986; Sharma et al EMBO J 1985) and the extent and degree of such binding was not specifically characterized. BiP/GRP78 may also associate with partially assembled proteins and retain them in the ER until assembly and processing is complete as is the case for the processing of immunoglobulin heavy chain (Bole et al J Cell Biol 1986).
  • This invention provides an anti-sense expression vector capable of directing the transcription of mRNA complementary to mRNA encoding GRP78 protein (BiP).
  • the anti-sense expression vector thus directs the transcription of "anti-sense" mRNA which is capable of hybridizing to part or all of the endogenous GRP78/BiP-encoding mRNA, thereby preventing translation of GRP78/BiP mRNA in a host cell transformed or transfected with the expression vector of this invention.
  • the anti-sense expression vector comprises a DNA sequence encoding part or all of a GRP78 protein or an expression control sequence thereof, operatively linked in reverse orientation to an expression control sequence permitting transcription of the anti-sense mRNA.
  • the anti-sense mRNA, and thus the corresponding DNA in the anti-sense expression vector (i) need not be full-length, i.e. may contain fewer bases or base pairs than the host cell's BiP-encoding mRNA or DNA, and/or (ii) may be mutagenized or otherwise contain a number of substituted bases or base pairs for naturally occurring ones, so long as the anti-sense mRNA hybridizes to a sufficient portion of the host cell's GRP78/BiP mRNA to prevent or significantly reduce GRP78/BiP mRNA translation.
  • the anti-sense expression vector may also contain one or more amplifiable markers permitting the amplification of gene copy number by conventional techniques, one or more selectable markers, and other elements heretofore generally known in the art to be useful in expression vectors, as disclosed in greater detail below.
  • Suitable anti-sense expression vectors may be synthesized by techniques well known in the art.
  • the components of the vectors such as bacterial replicons, selection genes, amplifiable markers, enhancers, promoters, and the like may be obtained from natural sources or synthesized by known procedures. See Kaufman et al., 1982, J. Mol. Biol., 159:601-621; Kaufman, 1985, Proc. Natl. Acad. Sci. 82:689-693.
  • the DNA sequence encoding the BiP anti-sense mRNA may be obtained or synthesized as described hereinafter.
  • This invention further encompasses an improved eucaryotic host cell for expressing a heterologous protein such as Factor VIII or analogs thereof; t-PA or variants thereof; von Willebrand Factor (VWF); erythropoietin; lymphokines such as GM-CSF, other CSFs, I1-2, I1-3; etc.
  • the improved host cell comprises a host cell transformed or transfected with an anti-sense expression vector of this invention.
  • the improved host cell may be a bacterial, yeast, fungal, plant, insect or mammalian cell or cell line, and is preferably a mammalian cell or cell line.
  • Established cell lines including transformed cell lines, are suitable as hosts.
  • Normal diploid cells cell strains derived from in vitro culture of primary tissue, as well as primary explants (including relatively undifferentiated cells such as hematopoetic stem cells) are also suitable.
  • Candidate cells need not be genotypically deficient in a selection gene so long as the selection gene is dominantly acting.
  • the host cells preferably will be established mammalian cell lines.
  • CHO Choinese Hamster Ovary
  • vector DNA may include all or part of the bovine papilloma virus genome (Lusky et al., 1984, Cell 36:391-401) and be carried in cell lines such as C127 mouse cells as a stable episomal element.
  • Other usable mammalian cell lines include HeLA, COS-1 monkey cells, melanoma cell lines such as Bowes cells, mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHK or HAK hamster cell lines and the like.
  • the improved host cell may further be transformed or transfected with an expression vector capable of directing the expression of the desired protein.
  • Suitable vectors for the expression of a large number of diverse proteins are known in the art and are either publicly available or may be synthesized by purely conventional techniques.
  • Vectors containing DNA encoding the following proteins, for example, have been deposited with the American Type Culture Collection (ATCC) of Rockville, MD: Factor VIII (pSP64-VIII, ATCC No. 39812); a Factor VIII analog, "LA”, lacking 581 amino acids (pDGR-2, ATCC No. 53100); t-PA and analogs thereof (see co-pending U.S. application Ser. No. 882,051); VWF (pMT2-VWF, ATCC No.
  • EPO pRK1-4, ATCC No. 39940
  • pdBPVMMTneo 342-12 BPV-type vector ATCC No. 37224
  • GM-CSF pCSF-1, ATCC No. 39754
  • An improved method for producing a heterlogous protein, e.g. Factor VIII, etc., by culturing a eucaryotic host cell transformed with a vector capable of directing the expression of a heterologous protein.
  • the improvement involves using as the host cell a host cell transformed or transfected with an anti-sense GRP78/BiP vector of this invention.
  • Stable transformants are then screened for decreased expression of BiP and/or expression of the heterologous protein by standard immunological or enzymatic assays.
  • the presence of anti-sense mRNA and/or DNA encoding the heterologous protein may be detected by standard procedures such as Northern or Southern blotting respectively.
  • Transient expression of the anti-sense vector and/or the DNA encoding the heterologous protein during the several days after introduction of the respective vectors(s) into COS-1 monkey cells is measured without selection by activity or immunological assay of the proteins in the culture medium.
  • the protein so produced may be recovered, purified, and/or characterized, all by known methods.
  • This invention also encompasses a "sense" GRP78/BiP expression vector which comprises a DNA sequence encoding GRP78/BiP operatively linked to an expression control sequence. Construction of an exemplary GRP78/BiP expression vector is described in detail below, but it should be understood that other BiP expression vectors may be readily prepared by purely conventional techniques using a GRP78/BiP-encoding DNA sequence and readily available or synthesizable components, as is true for other exemplary vectors of this invention described hereinafter.
  • This invention also encompasses a eucaryotic host cell, as described above, but which is transformed or transfected with a GRP78/BiP expression vector.
  • a eucaryotic host cell as described above, but which is transformed or transfected with a GRP78/BiP expression vector.
  • Such an engineered host cell may be further transformed with an expression vector capable of directing the transcription of a heterologous protein, also as described above.
  • the resultant cell may then be cultured in an improved method for producing the heterologous protein, wherein improperly glycosylated or folded heterologous protein is not secreted into the culture medium, but is instead retained within the host cell by virtue of association with intracellular BiP.
  • FVIII human factor VIII
  • tPA human tissue plasminogen activator
  • vWF von Willebrand Factor
  • FVIII is synthesized as a single chain precursor of about 250 kd and subsequently processed to a "heavy chain" of about 200 kd and a "light chain” doublet of about 80 kd.
  • FVIII has a plethora of potential N-linked glycosylation sites. Twenty of the twenty-five sites are located within the middle one-third of the molecule which has been defined as the B domain.
  • tPa has a molecular weight of about 68,000 kd and contains four potential N-linked glycosylation sites of which three are typically occupied (Pohl et al. Biochem 1984).
  • vWF is a large glycoprotein synthesized as an approximately 260,000 kd precursor which forms dimers in the endoplasmic reticulum and is subsequently processed in Golgi and post-Golgi compartments to approximately 100,000 and 220,000 kd forms (Bonthron et al. Nature 1986). These processed forms undergo interdimer disulfide bond formation to form high molecular weight multimers (Wagner & Marder J. Cell Biol 1984).
  • LA is a deleted form of FVIII which has only 7 potential N-linked sites compared to 25 on wt FVIII.
  • Single chain LA appears as a doublet of approximately 150 kd.
  • BiP protein induced by tunicamycin treatment which comigrates with the protein identified as BiP by immunoprecipitation with the anti-BiP monoclonal.
  • the molecular weight of BiP does not change following tunicamycin treatment indicating it is not normally N-linked glycosylated.
  • vWF complex glycoprotein
  • the precursor form of vWF has 17 N-linked glycosylation sites spread along the molecule.
  • the 260 Kda VWF precursor protein is observed inside CHO cells. Roughly 20% of this protein is found complexed with BiP.
  • VWF is efficiently and rapidly secreted such that at the 4 h chase point approximately 90% of the 260 kda precursor is gone from the cell extract and the conditioned medium contains the processed forms of 275 and 220 kD.
  • T-PA has 4 potential N-linked glycosylation sites of which 3 are utilized.
  • t-PA appears as a doublet or roughly 68 kD due to variability in the utilization of one of the three glycosylation sites.
  • t-PA3x is genetically engineered mutant in which the three normally utilized N-linked glycosylation sites have been abolished by Asn to Gln codon changes in the canonical recognition site sequences. See International Application No. PCT/US87/00257 (WO 87/04722).
  • t-PAwt Glycosylated unmodified t-PA (i.e. wild type, "t-PAwt") was efficiently processed and secreted in a high producing CHO cell line, AJ19.
  • t-PAwt exhibited a slight association with BiP.
  • t-PAwt During the 1 h and 3 h chase periods most of the t-PAwt had been secreted into the medium and little if any association with BiP could be detected intracellularly at these times.
  • t-PAwt is correctly processed and secreted without extensive detectable association with BiP.
  • t-PA3x-13 produces roughly 200-fold higher levels of t-PA3x that t-PA3x-4.
  • t-PA3x displays a significant association with BiP in sharp contrast to that observed for the t-PA3x-4 line.
  • the amount of t-PA3x associated with BiP decreases slightly between the pulse time point and the 1 h chase point.
  • the amount of t-PA3x found in a complex with BiP remains the same between the 1 h and 3 h chase points.
  • Another way to examine unglycosylated forms of t-PA is to inhibit N-linked glycosylation by tunicamycin treatment. Immunofluorescence analysis showed that tunicamycin treatment of t-PAwt-producing cells results in accumulation of t-PA in the endoplasmic reticulum. When the AJ19 cell line is treated with 10 ug/ml tunicamycin for 1 hour the association of the unglycosylated t-PA with BiP is significantly increased compared to t-PAwt. t-PA-BiP complex is detected at the chase time point and there is some inhibition of secretion.
  • t-PAwt treated with tunicamycin profile looks very much like that of t-PA3x at high expression levels. In both cases a similar proportion of the unglycosylated molecules are apparently not competent for efficient secretion and remain in an intracellular complex with BiP. At lower expression levels t-PA3x shows no significant association with BiP. t-PAwt at lower expression levels is affected to a lesser degree by tunicamycin treatment that the high producer cell line. Thus the association of unglycosylated t-PA with BiP is influenced by the intracellular levels of t-PA.
  • t-PA Unglycosylated t-PA appears as doublet in these experiments.
  • t-PA is synthesized with a 12-15 amino acid long propeptide at the amino terminus of the protein (Pennica et al. Nature 1983). Most probably the higher molecular weight band represents the uncleaved pro-t-PA precursor form while the lower band represents the mature form which has been processed to remove the amino terminal propeptide. Since propeptide cleavage occurs in Golgi and post-Golgi compartments and BiP has been localized to the endoplasmic reticulum, only the pro-t-PA precursor form should be present in the same compartment as BiP. Consistent with this interpretations is the observation that only the higher molecular weight species of the doublet is found associated with BiP while only the lower molecular weight species is secreted.
  • a cDNA coding sequence for Chinese hamster GRP78 was placed in the expression vector pMT2 which is a derivative of p91023b and this expression vector (pMTGRP78) was cotransfected into COS cells with wt FVIII (pMT2VIII) or LA (pMT2LA) expression vectors to examine the consequences of overexpression of GRP78 on FVIII secretion.
  • the transient expression of FVIII was monitored by assaying the conditioned medium for FVIII activity. Expression of GRP78 was detected by immunoprecipitation with the anti-BiP monoclonal.
  • pMT2 may be obtained from pMT2-vWF (ATCC No. 67122) as described in detail below.
  • Coexpression of GRP78 and FVIII in COS cells consistently resulted in a 6-10 fold reduction in the levels of FVIII activity in the conditioned medium (Table 1, below).
  • the effect of two different replicating vectors in the same cell is a decrease in the expression of both vectors.
  • FVIII or LA vectors were always cotransfected with pCSF-1.
  • pCSF-1 is an expression vector for GM-CSF which carries similar replication and transcription elements as pMT2 (Wong et al Science 1985).
  • Coexpression of LA and GRP78 in COS cells resulted in a 2-3 fold reduction the levels of LA activity in the medium.
  • the degree of decrease of activity of LA and wt FVIII are consistent with the degree of association of FVIII and LA with BiP in CHO cells.
  • the heavily glycosylated wt FVIII is more affected by GRP78 expression than LA in the transient COS system and also displays a stronger association with BiP in stable CHO cell lines. This data indicates that high levels of GRP78 can interfere with the secretion of FVIII and is suggestive that BiP and GRP78 are functionally and structurally similar.
  • GRP78 cDNA used is a matter of choice.
  • a Chinese hamster cDNA clone p3C5 obtained as described (Lee et al, 1983, J. Biol. Chem. 258:597).
  • a rat cDNA clone may be obtained, also as described (Munro & Pelham Cell 1986). Sequence analysis has shown that both of these clones encode the same protein identified as GRP78. At the amino acid level the rat and hamster proteins are 99.4% homologous.
  • Cloning of a functional GRP78 cDNA may be effected using one or more oligonucleotides derived from the published sequence of GRP78 and purely conventional techniques as described by Lee et al. or Munro & Pelham, supra.
  • a cloned rat cDNA may be obtained from Sean Munro, MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, England.
  • Chinese hamster GRP78 cDNA was placed into a mammalian expression vector pMT2.
  • This vector is a derivative of p91023B and may be obtained by EcoRI digestion of pMT2-vWF, which has been deposited with the American Type Culture Collection under ATCC No. 67122. EcoRI digestion excises the cDNA insert present in pMT2-vWF, yielding pMT2 in linear form which can be ligated and used to transform E. coli HB101 or DH5 to ampicillin resistance. Plasmid pMT2 DNA can then be prepared by conventional methods. The 1962 nucleotide open reading frame encoding hamster GRP78 was excised by PstI and EcoRV digestion.
  • the vector was prepared by EcoRI digestion, the EcoRI ends were filled in using Klenow fragment and then the vector was digested with PstI. The fragment from the hamster clone was ligated into the prepared pMT2 vector, although as indicated previously, other eucaryotic expression vectors may also be used.
  • the resultant plasmid pMTGRP78 contains the adenovirus-VA genes, SV40 replication origin including enhancer, adenovirus major late promoter including tripartite leader and 5' donor splice site, 3' splice acceptor site, GRP78 cDNA insert, DHFR cDNA insert, SV40 early polyadenylation site and pBR322 sequences.
  • pMTGRP78 was used to cotransfect COS-1 cells along with the FVIII expression vectors pMT2VIII or pMT2LA (Toole et al Proc. Natl. Acad. Sci. U.S.A. 1986) using the DEAE dextran procedure (Kaufman Proc. Natl. Acad. Sci. U.S.A. 1985). Conditioned medium was harvested at various times beginning 48 hours post-transfection and assayed for FVIII activity as described (Toole et al Nature 1984). The results of these experiments are summarized in Table I. Previous work has shown that cotransfection of two different expression vectors reduces the level of expression compared to transfection of a single vector.
  • pCSF-1 a previously described vector which expresses GM-CSF (Wong et al Science 1985).
  • pCSF-1 is available from the American Type Culture Collection in E. coli MC1061 as ATCC 39754.
  • Table I show that coexpression of GRP78 and FVIII resulted in roughly six-ten fold reduction in the level of secreted FVIII activity and coexpression of GRP78 and LA resulted in a roughly two-three fold reduction compared to coexpression of FVIII or LA with GM-CSF.
  • Chinese hamster GRP78 cDNA was placed into pMT2 in the opposite orientation from that in the above-described expression vector.
  • the 1962 nucleotide open reading frame was excised as follows.
  • the hamster GRP78 clone was digested with EcoRV and a PstI linker was ligated to the blunt EcoRV end.
  • the DNA was then cut with PstI to excise the 1962 bp open reading frame.
  • the vector pMT2 was prepared by digestion with PstI. The fragment from the hamster was ligated into the PstI site of pMT2.
  • the resultant plasmid pMT ⁇ B2 was identified by extensive restriction digest mapping to carry the GRP78 cDNA sequences such that the 3' end of the GRP78 cDNA ATCC No. 40387 was closest to the adenovirus major late promoter.
  • transcripts expressed from the adenovirus major late promotor would contain sequence which is the complement of the GRP78 coding sequence.
  • a RNA is commonly referred to as an antisense RNA. It has been reported that antisense RNA can interact intracellularly with its complementary sense mRNA and block the synthesis of the encoded protein (Kim and Wold Cell 1985).
  • pMT ⁇ B2 was used to cotransfect COS-1 cells along with the FVIII expression vector pMT2VIII using the DEAE dextran procedure.
  • Conditioned medium was harvested at various times beginning 48 hours post-transfection and assayed for FVIII activity.
  • Table II The results of such an experiment are summarized in Table II.
  • coexpression of FVIII and antisense GRP78 sequences resulted in a 50% increase in FVIII activity in the conditioned medium compared to coexpression of FVIII and GM-CSF. This data indicates that the introduction of an antisense vector to decrease the intracellular level of GRP78 can result in increased level of FVIII secretion.
  • CHO cell lines which are DHFR deficient, CHO - (DUKX-Bll), were grown in an alpha medium supplemented with 10 ⁇ g/ml each of thymidine, deoxyadenosine and adenosine.
  • Cells were cotransfected with pMT ⁇ B2 (20 ⁇ g) and pSV2Neo (2 ⁇ g)(ATCC No. 37149) by the calcium phosphate coprecipitation procedure (Kaufman et al JMB 1982).
  • pSV2Neo codes for resistance to the antibiotic G418 (P. Southern & Berg P. 1982 J. Mol. Appl. Genet. l 327-341).
  • pMT ⁇ B2 contains an intact DHFR coding region in the 3' region of the antisense GRP78 transcript.
  • G418 resistant transformants can be subsequently selected for DHFR expression from this mRNA.
  • Growth in alpha media lacking nucleosides with 10% dialyzed fetal calf serum resulted in DHFR + colonies.
  • Five colonies were pooled to produce the A6B line. This line was then amplified by selection for growth in the presence of the folic acid analogue methotrexate at a concentration of 0.02 ⁇ M.
  • the BiP/GRP78 level in A6B was compared to CHO DUKX by immunoprecipitation of radiolabeled cell extracts with anti-BiP monoclonal and analysis by SDS PAGE.
  • A6B showed reduced levels of BiP/GRP78 compared to the original CHO line.
  • the level of antisense GRP78 RNA derived from pMT ⁇ B2 in these cells was determined by Northern analysis.
  • the A6B cell line was fused with an FVIII producing cell line H9 by standard polyethylene glycol procedure following treatment of A6B with DEPC to render them nonviable (W. E. Wright, Chap 5, The Selection of Heterokaryons and Cell Hybrids Using the Biochemical Inhibitors Iodoacetamide and Diethylpyrocarbonate in Techniques in Somatic Cell Genetics, Ed. J. W. Shay, Plenum Press).
  • Two days following cell fusion the cells were plated in 1 ⁇ M methetrexate and 1 mg/ml G418.
  • H9 grows in 1 ⁇ M methetrexate and G418 selects for the chromosome containing the antisense GRP78 sequences derived from A6B cells.
  • H9xA6B-9 After eleven days of growth twenty-two colonies were pooled to produce the cell line designated H9xA6B-9. Determination to the level of FVIII procoagulant activity secreted into the conditioned medium by H9xA6B-9 showed that this cell line yielded two-fold greater activity than the original H9 line.
  • wt FVIII is associated with BiP and most of the FVIII which is never secreted remains associated with BiP. 20 out of 25 N-linked glycosylation sites are clustered in middle third of the FVIII protein.
  • LA a deleted form of FVIII which has 18 of 20 clustered glycosylation sites removed, is more efficiently secreted than wt FVIII exhibits a transient association with BiP.
  • VWF a complex glycoprotein which is efficiently secreted by CHO cells, exhibits only a transient association with BiP.
  • the 17 glycosylation sites on VWF are spaced along the molecule rather than clustered as on wt FVIII.
  • tPA exhibits only a slight transient association with BiP.
  • tunicamycin results in the intracellular retention of some of the unglycosylated molecules in a complex with BiP.
  • tPA3x an engineered mutant of t-PA which has had three potential N-linked glycosylation sites abolished by replacement of Asn with Gln exhibits only a slight association with BiP at low expression levels. However, at high expression levels a fraction of the unprocessed protein displays a stable association with BiP and is apparently not secreted effeciently. This behavior is similar th that observed for wt t-PA when glycosylation is inhibited.
  • Intracellular retention of unglycosylated tPA in a complex with BiP is dependent on expression level. tPA3x at low expression levels is not associated with BiP and is effeciently secreted. At 200-fold higher expression levels a significant proportion of tPA3x is associated with BiP. This intracellular retention is similar to that observed for the high producer wt tPA cell line, AJ19, when N-linked glycosylation is inhibited. In a low producing wt tPA cell line, H12B, the effect of inhibition of N-linked glycosylation is less pronounced than in cells such as AJ19. This suggests that unglycosylated tPA may aggregate when present at high concentrations in the ER leading to its association with BiP.
  • BiP may associate with improperly glycosylated or folded proteins in the endoplasmic reticulum and prevent their secretion. BiP probably functions to clear aggregated proteins from the endoplasmic reticulum in an analogous function to hsp70 in heat shocked nucleoli. The problem of protein aggregation or insolubility in the ER may be exacerbated by the high expression levels now attainable by recombinant DNA expressioin techniques and for some glycoproteins such as FVIII aggregation and consequent association with BiP may prove a barrier to high level secretion.
  • the 20 clustered glycosylation sites in the middle of wt FVIII may be inefficiently glycosylated resulting in aggregation of improperly folded molecules and stable assoc'n with BiP. It is also possible that this heavily glycosylated domain assumes a conformation which BiP recognizes as aberrant even if N-linked glycosylation is appropriate. In this situation secretion competent molecules may be trapped in a complex with BiP and reduced levels of BiP may result in higher levels of secretion.
  • Uncoating ATPase is a member of the 70- kD family of stress proteins. Cell 45:3-13.
  • Tissue plasminogen activator peptide analysis confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences. Biochemistry 23, 3701-3707.

Abstract

This invention provides vectors, improved host cells and improved methods for producing a heterologous protein by culturing an improved eucaryotic host cell of this invention transformed or transfected with a vector capable of directing the expression of the heterologous protein. The preferred improved host cell of this invention is a mammalian host cell containing and capable of expressing an anti-sense GRP78 DNA sequence.

Description

This application is a continuation in part of U.S. Ser. No. 931,381, filed 14 Nov. 1986 (now abandoned).
BACKGROUND OF THE INVENTION
This invention relates to improvements in the expression and secretion of heterologous proteins from eucaryotic cells. Complete citations for references cited herein are set forth immediately preceding the claims.
The information which determines the destiny of a secreted protein is contained in its primary structure, and much of this information may involve dictating appropriate post-translational modification and correct conformation. The steps in the exocytotic pathway of the processing and transit of membranespanning and secretory proteins in mammalian cells have been described (for reviews see Farquhar Ann Rev Cell Biol 1985; Kornfeld & Kornfeld Ann Rev Biochem 1985). A large body of work has shown that proteins destined for the cell surface are first cotranslationally translocated into the lumen of the endoplasmic reticulum (ER) mediated by a signal sequence at or near the amino terminus of the nascent chain (Blobel & Dobberstein J. Cell Biol 1975; Walter et al Cell 1984). Inside the endoplasmic reticulum the signal sequence is usually removed and a high mannose oligosaccharide core unit is transferred to a sparagine residues located in the sequence Asn-X-Ser/Thr where X can be any amino acid, except perhaps proline. This N-linked core glycosylation occurs cotranslationally and it appears that the efficiency of glycosylation is dependent on the presentation of an appropriate conformation of the peptide chain as it enters the endoplasmic reticulum. Potential N-linked glycosylation sites may no longer be accessible after the protein has folded (Kornfeld & Kornfeld).
Proteins move from the endoplasmic reticulum to the Golgi apparatus where modifications such as sulfation and processing of the high mannose oligosaccharide chain to a complex type occurs and the proteins are directed to their proper destinations (Dunphy & Rothman Cell 1985). The movement from the ER to the Golgi has been identified as the rate limiting step in intracellular transport (Lodish et al. Nature 1983; Fitting & Kabat JBC 1982 J. Cell Biol 1985). Few proteins resident in the ER have been extensively studied for their interaction with secretory proteins transiting that compartment.
Environmental stresses such as heat shock induce the synthesis in prokaryotic and eukaryotic cells of a set of highly conserved heat shock proteins. (Schlesinger, J. Cell Biol 1986). hsp70 is the most abundant of these induced proteins. Proteins related to hsp70 are found in unstressed mammalian cells. There are three main members of the mammalian hsp70-like group of proteins: hsp70, hsc70, and GRP78 (Pelham Cell 1986) Following heat shock, synthesis of hsp70 is induced and the protein migrates to the nucleus where it is found in tight association with nucleoli. hsp70 can be released from this association by the addition of ATP in vitro. It has been hypothesized that hsp70 disaggregates heat damaged proteins by an ATP dependent mechanism to facilitate recovery from heat shock (Lewis & Pelham EMBO J 1985). hsc70 is found at high basal levels in growing cells and is only slightly heat inducible (Pelham Cell 1986). hsc70 has recently been identified as "uncoating ATPase", a constitively expressed enzyme that releases clathrin triskelions from coated vesicles in an ATP dependent reaction (Chappell et al Cell 1986, Ungewickell EMBO J 1985).
GRP78 was initially reported to be one of two proteins whose synthesis was induced by glucose starvation in chick fibroblasts (Shiu et al Proc. Natl. Acad. Sci. U.S.A. Its synthesis can also be induced by inhibitors of N-linked glycosylation such as tunicamycin, glucosamine or 2-deoxyglucose (Olden et al Proc. Natl. Acad. Sci. U.S.A 1979, Pouyssegur et al Cell 1977). GRP78 is not heat inducible and its basal level is high in secreting cells. Recently it has been shown that GRP78 is similar if not identical to immunoglobulin heavy chain binding protein (BiP) (Munro and Pelham Cell 1986). GRP78 is therefore also referred to hereinafter as BiP/GRP78 or simply, BiP. BiP was first described for its association with immunoglobulin heavy chains in pre-B cells (Haas and Wable Nature 1983). BiP transiently complexes with immunoglobulin heavy chain in the endoplasmic reticulum of secreting hybridomas. When assembly with light chains occurs BiP dissociates from the complex. In the absence of light chains BiP remains associated with heavy chains and this complex is not transported from the endoplasmic reticulum to the Golgi apparatus (Bole et al J. Cell Biol 1986). These subcellular fractionation studies showed that BiP is predominantly localized to the endoplasmic reticulum. The heavy chain-Bip complex can be dissociated in the presence of ATP suggesting a functional analogy with the hsp70 complex in heat shocked nucleoli. (Munro & Pelham Cell 1986).
We believe that BiP/GRP78 may associate in secreting cells with underglycosylated or improperly folded proteins in the endoplasmic reticulum and help clear them in analogy to the hypothesized role of hsp70 in the nucleus (Pelham Cell 1986). Such a function is consistent with the induction of increased levels of GRP78 synthesis under conditions which disrupt N-linked glycosylation. Recent studies on abberant proteins which fail to transit out of the ER have been interpreted to show that BiP binds to them in the ER although the identity of grp78 and BiP was disputed (Gething et al Cell 1986; Sharma et al EMBO J 1985) and the extent and degree of such binding was not specifically characterized. BiP/GRP78 may also associate with partially assembled proteins and retain them in the ER until assembly and processing is complete as is the case for the processing of immunoglobulin heavy chain (Bole et al J Cell Biol 1986).
Independent of the research on BiP mentioned above, we have conducted extensive research on the production of glycoproteins, including Factor VIII, in genetically engineered host cells. In the course of this research we have surprisingly found that a significant proportion of Factor VIII produced in vitro, e.g. in CHO cells, is not secreted into the cell culture medium. We have now surprisingly found that secretion levels for Factor VIII and other glycoproteins can be decreased by providing higher intracellular levels of BiP and can be increased by reducing the intracellular BiP level.
SUMMARY OF THE INVENTION
This invention provides an anti-sense expression vector capable of directing the transcription of mRNA complementary to mRNA encoding GRP78 protein (BiP). The anti-sense expression vector thus directs the transcription of "anti-sense" mRNA which is capable of hybridizing to part or all of the endogenous GRP78/BiP-encoding mRNA, thereby preventing translation of GRP78/BiP mRNA in a host cell transformed or transfected with the expression vector of this invention. The anti-sense expression vector comprises a DNA sequence encoding part or all of a GRP78 protein or an expression control sequence thereof, operatively linked in reverse orientation to an expression control sequence permitting transcription of the anti-sense mRNA. The anti-sense mRNA, and thus the corresponding DNA in the anti-sense expression vector, (i) need not be full-length, i.e. may contain fewer bases or base pairs than the host cell's BiP-encoding mRNA or DNA, and/or (ii) may be mutagenized or otherwise contain a number of substituted bases or base pairs for naturally occurring ones, so long as the anti-sense mRNA hybridizes to a sufficient portion of the host cell's GRP78/BiP mRNA to prevent or significantly reduce GRP78/BiP mRNA translation. The anti-sense expression vector may also contain one or more amplifiable markers permitting the amplification of gene copy number by conventional techniques, one or more selectable markers, and other elements heretofore generally known in the art to be useful in expression vectors, as disclosed in greater detail below.
Suitable anti-sense expression vectors, as are described in greater detail herein, may be synthesized by techniques well known in the art. The components of the vectors such as bacterial replicons, selection genes, amplifiable markers, enhancers, promoters, and the like may be obtained from natural sources or synthesized by known procedures. See Kaufman et al., 1982, J. Mol. Biol., 159:601-621; Kaufman, 1985, Proc. Natl. Acad. Sci. 82:689-693. The DNA sequence encoding the BiP anti-sense mRNA may be obtained or synthesized as described hereinafter.
This invention further encompasses an improved eucaryotic host cell for expressing a heterologous protein such as Factor VIII or analogs thereof; t-PA or variants thereof; von Willebrand Factor (VWF); erythropoietin; lymphokines such as GM-CSF, other CSFs, I1-2, I1-3; etc. The improved host cell comprises a host cell transformed or transfected with an anti-sense expression vector of this invention. The improved host cell may be a bacterial, yeast, fungal, plant, insect or mammalian cell or cell line, and is preferably a mammalian cell or cell line.
Established cell lines, including transformed cell lines, are suitable as hosts. Normal diploid cells, cell strains derived from in vitro culture of primary tissue, as well as primary explants (including relatively undifferentiated cells such as hematopoetic stem cells) are also suitable. Candidate cells need not be genotypically deficient in a selection gene so long as the selection gene is dominantly acting.
The host cells preferably will be established mammalian cell lines. For stable integration of vector DNA into chromosomal DNA, and for subsequent amplification of the integrated vector DNA, both by conventional methods, CHO (Chinese Hamster Ovary) cells are presently preferred. Alternatively, vector DNA may include all or part of the bovine papilloma virus genome (Lusky et al., 1984, Cell 36:391-401) and be carried in cell lines such as C127 mouse cells as a stable episomal element. Other usable mammalian cell lines include HeLA, COS-1 monkey cells, melanoma cell lines such as Bowes cells, mouse L-929 cells, 3T3 lines derived from Swiss, Balb-c or NIH mice, BHK or HAK hamster cell lines and the like.
The improved host cell may further be transformed or transfected with an expression vector capable of directing the expression of the desired protein. Suitable vectors for the expression of a large number of diverse proteins are known in the art and are either publicly available or may be synthesized by purely conventional techniques. Vectors containing DNA encoding the following proteins, for example, have been deposited with the American Type Culture Collection (ATCC) of Rockville, MD: Factor VIII (pSP64-VIII, ATCC No. 39812); a Factor VIII analog, "LA", lacking 581 amino acids (pDGR-2, ATCC No. 53100); t-PA and analogs thereof (see co-pending U.S. application Ser. No. 882,051); VWF (pMT2-VWF, ATCC No. 67122); EPO (pRK1-4, ATCC No. 39940; pdBPVMMTneo 342-12 (BPV-type vector) ATCC No. 37224); and GM-CSF (pCSF-1, ATCC No. 39754).
An improved method is thus provided for producing a heterlogous protein, e.g. Factor VIII, etc., by culturing a eucaryotic host cell transformed with a vector capable of directing the expression of a heterologous protein. The improvement involves using as the host cell a host cell transformed or transfected with an anti-sense GRP78/BiP vector of this invention.
Stable transformants are then screened for decreased expression of BiP and/or expression of the heterologous protein by standard immunological or enzymatic assays. The presence of anti-sense mRNA and/or DNA encoding the heterologous protein may be detected by standard procedures such as Northern or Southern blotting respectively. Transient expression of the anti-sense vector and/or the DNA encoding the heterologous protein during the several days after introduction of the respective vectors(s) into COS-1 monkey cells is measured without selection by activity or immunological assay of the proteins in the culture medium.
Following expression of the DNA encoding the heterologous protein, the protein so produced may be recovered, purified, and/or characterized, all by known methods.
This invention also encompasses a "sense" GRP78/BiP expression vector which comprises a DNA sequence encoding GRP78/BiP operatively linked to an expression control sequence. Construction of an exemplary GRP78/BiP expression vector is described in detail below, but it should be understood that other BiP expression vectors may be readily prepared by purely conventional techniques using a GRP78/BiP-encoding DNA sequence and readily available or synthesizable components, as is true for other exemplary vectors of this invention described hereinafter.
This invention also encompasses a eucaryotic host cell, as described above, but which is transformed or transfected with a GRP78/BiP expression vector. Such an engineered host cell may be further transformed with an expression vector capable of directing the transcription of a heterologous protein, also as described above. The resultant cell may then be cultured in an improved method for producing the heterologous protein, wherein improperly glycosylated or folded heterologous protein is not secreted into the culture medium, but is instead retained within the host cell by virtue of association with intracellular BiP.
DETAILED DESCRIPTION OF THE INVENTION
We have examined the role of BiP/GRP78 in the processing and secretion of a variety of proteins, including human factor VIII (FVIII), human tissue plasminogen activator (tPA) and human von Willebrand Factor (vWF) in host cells such as stable Chinese hamster ovary (CHO) cell lines. FVIII is synthesized as a single chain precursor of about 250 kd and subsequently processed to a "heavy chain" of about 200 kd and a "light chain" doublet of about 80 kd. FVIII has a plethora of potential N-linked glycosylation sites. Twenty of the twenty-five sites are located within the middle one-third of the molecule which has been defined as the B domain. (Toole et al Nature 1984) Deletion of this domain to produce the "LA" variant of FVIII results in higher levels of FVIII secretion (Toole et al Proc. Natl. Acad. Sci. U.S.A. 1986). tPa has a molecular weight of about 68,000 kd and contains four potential N-linked glycosylation sites of which three are typically occupied (Pohl et al. Biochem 1984). vWF is a large glycoprotein synthesized as an approximately 260,000 kd precursor which forms dimers in the endoplasmic reticulum and is subsequently processed in Golgi and post-Golgi compartments to approximately 100,000 and 220,000 kd forms (Bonthron et al. Nature 1986). These processed forms undergo interdimer disulfide bond formation to form high molecular weight multimers (Wagner & Marder J. Cell Biol 1984).
Our results indicate that the occupancy of N-linked glycosylation sites on a protein plays a role in the extent of BiP association. Underglycosylation of a protein results in increased BiP association and retention inside the cell. This block to secretion may be dependent on expression level. We believe that BiP/GRP78 plays a major role in the processing and transport of secreted glycoproteins.
RESULTS Association of FVIII and Deleted Form LA with BiP
In order to qualitatively assess the role of BiP/GRP78 in the secretory pathway we examined a variety of stable CHO cell lines by pulse and chase experiments. The time course of association of FVIII and BiP was analyzed by comparing the amount of FVIII which was detected by immunoprecipitation with a monoclonal antibody specific for BiP against that precipitated with a monoclonal specific for FVIII. Following a 1 hour pulse with 35 S methionine roughly 85% of wild-type (wt) FVIII was detected in a complex with BiP as indicated by the amount of FVIII seen in the anti-BiP immunoprecipitation compared to that precipitated by the anti-FVIII monoclonal. Only the 250 kD single chain form was found to be associated with BiP. No processed 80 kD form was precipitated by the anti-Bip monoclonal although it is present in the cells at this time. BiP was observed to migrate slightly faster than the 80 kD doublet.
At the 4 h chase time point processed heavy chain of 200 kD and the 80 kD light chain doublet can be detected in the conditioned medium. Immunoprecipation of the conditioned medium detected a slight amount of BiP. However there was no associated FVIII observed. Intracellularly the amount of FVIII associated with BiP had decreased to less than 50% as the molecule transits through the cell. At the 20 h chase time point the ratio of BiP-associated to unassociated FVIII changed. The single chain FVIII had begun to degrade as indicated by a smearing of the 250 kD band as analyzed by gel electrophoresis and roughly all of this FVIII which remained in the cell after a long chase was found complexed with BiP. The amount of BiP had increased in the conditioned medium over this time course but an association with secreted FVIII can not be detected. It is worth noting that through the 20 h chase time course the amount of GRP78 inside the cells does not significantly change. It is secreted or released from damaged cells at a low rate and appears to be stable cellular protein with a half life greater than 20 h.
We then examined the association of LA with BiP in a similar time course. LA is a deleted form of FVIII which has only 7 potential N-linked sites compared to 25 on wt FVIII. At the 1 h pulse time point roughly 60% of single chain LA is associated with BiP. Single chain LA appears as a doublet of approximately 150 kd. As with wt FVIII no 80 kd forms are observed to be complexed with BiP.
During the 4 h chase period the association of LA and BiP significantly decreases compared to the earlier time point. Single chain, processed heavy chain which migrates as a smear around 90 kD, and 80 kD light chain doublet can be detected in the 4 h conditioned medium by immunoprecipitation with anti-FVIII monoclonal. Also present in the medium is trace unassociated BiP. At the 20 h chase time point a small amount of LA remains in the cell and the proportion of LA associated with BiP is slight. These experiments indicated that LA exhibits a transient association with BiP inside the cell and, in contrast to wt FVIII, is not retained intracellularly in a complex with BiP. This suggested that the complexity of the wt FVIII glycosylation may influence the degree of BiP association since deletion of the highly glycosylated region in LA produced a protein which was associated with BiP to a lesser degree than wt FVIII. In this regard it is noteworthy that GRP78 is induced to high levels in CHO cells placed under conditions which affect N-linked glycosylation such as glucose starvation or tunicamycin treatment.
THE EFFECT OF TUNICAMYCIN ON THE ASSOCIATION OF LA AND BIP
This observation that a population of wt FVIII molecules remained inside the cell complexed with BiP after long chase while LA displayed a transient association prompted us to test whether disruption of the glycosylation of LA would result in greater association with BiP. To examine this concept, LA producing cells were treated overnight with 10 ug/ml tunicamycin. This treatment inhibits N-linked glycosylation and has been reported to induce increased levels of GRP78 synthesis (Munro and Pelham, 1986). Following a 1 h pulse with 35 S methionine the extracts of untreated or treated cells were immunoprecipitated with anti-FVIII monoclonal or anti-Bip monoclonal. In the absence of tunicamycin, only a small amount of single chain LA at 150 kd was associated with BiP. In the presence of tunicamycin the molecular weight of the LA doublet was reduced and roughly all of this unglycosylated LA was now associated with BiP. Thus disruption of the glycosylation of LA under conditions which should induce increased levels of GRP78 results in increased association with BiP compared to normally glycosylated LA. This suggested that improper glycosylation of FVIII might influence its association with BiP.
Of particular interest is the detection of a protein induced by tunicamycin treatment which comigrates with the protein identified as BiP by immunoprecipitation with the anti-BiP monoclonal. The molecular weight of BiP does not change following tunicamycin treatment indicating it is not normally N-linked glycosylated.
ASSOCIATION OF VWF WITH BIP
It was possible that the CHO cells were deficient in some aspect of the secretory pathway and so could not properly process a complex glycoprotein. To explore this we examined the processing of vWF in a stable CHO line in a pulse and chase experiment. The precursor form of vWF has 17 N-linked glycosylation sites spread along the molecule. At the 1 h pulse time point the 260 Kda VWF precursor protein is observed inside CHO cells. Roughly 20% of this protein is found complexed with BiP. VWF is efficiently and rapidly secreted such that at the 4 h chase point approximately 90% of the 260 kda precursor is gone from the cell extract and the conditioned medium contains the processed forms of 275 and 220 kD. These processed forms are not observed intracellularly to any significant degree, consistent with observations that this processing of the 260 kda precursor to the 275 and 220 forms occurs rapidly late in the pathway of VWF secretion. At both the 4 h chase and 20 h chase points most of the VWF has been secreted from the cells. Some VWF is still associated with BiP at the 4 h point but little if any BiP-VWF complex is observed at the 20 h chase point. Despite the fact that VWF is a complex glycosylated protein its association with BiP is transient and most of the protein is efficiently secreted from CHO cells. This is in contrast to the situation with wt FVIII and indicates that CHO cells are competent to efficiently secrete a complex glycoprotein.
ASSOCIATION OF TPA WITH BIP
To further analyze the role of glycosylation on protein secretion and Bip association we examined the processing of t-PA in glycosylated and unglycosylated forms in CHO cells. T-PA has 4 potential N-linked glycosylation sites of which 3 are utilized. t-PA appears as a doublet or roughly 68 kD due to variability in the utilization of one of the three glycosylation sites. t-PA3x is genetically engineered mutant in which the three normally utilized N-linked glycosylation sites have been abolished by Asn to Gln codon changes in the canonical recognition site sequences. See International Application No. PCT/US87/00257 (WO 87/04722).
Glycosylated unmodified t-PA (i.e. wild type, "t-PAwt") was efficiently processed and secreted in a high producing CHO cell line, AJ19. At the pulse time point t-PAwt exhibited a slight association with BiP. During the 1 h and 3 h chase periods most of the t-PAwt had been secreted into the medium and little if any association with BiP could be detected intracellularly at these times. Thus, at high intracellular concentrations t-PAwt is correctly processed and secreted without extensive detectable association with BiP.
We next examined the processing of t-PA3x in a low producing cell line, t-PA3x-4, to determine if the absence of N-linked glycosylation in t-PA3x would prevent its efficient secretion, in analogy to our observations with LA. This unglycosylated form of t-PA displays little association with BiP and is efficiently secreted into the medium. The time course of its transit through the cell is similar to that observed for t-PAwt. The majority of the protein has left the cell by the 1 h and 3 h chase time points indicating that t-PA3x does not experience a block in the secretory pathway. Thus, in the absence of glycosylation t-PA remains in a secretion competent form which displays little association with BiP.
However, examination of a high producing t-PA3x cell line, t-PA3x-13, indicated that the association of t-PA3x with BiP is dependent on the expression level. t-PA3x-13 produces roughly 200-fold higher levels of t-PA3x that t-PA3x-4. At high expression levels t-PA3x displays a significant association with BiP in sharp contrast to that observed for the t-PA3x-4 line. The amount of t-PA3x associated with BiP decreases slightly between the pulse time point and the 1 h chase point. However, the amount of t-PA3x found in a complex with BiP remains the same between the 1 h and 3 h chase points. Strikingly, the proportion of t-PA3x associated with BiP increased through the time course such that at the 3 h chase point most of the t-PA3x which remained in the cell was in a complex with BiP. During the time course of this experiment t-PA3x is secreted from the cell but there exists a population of the molecules which are not competent for efficient secretion and apparently enter a stable complex with BiP. This situation is highly reminiscent of that observed with wt FVIII described above. In the case of t-PA3x the efficient of secretion and the extent of BiP association of the unglycosylated protein was influenced by the expression level.
The Effect of Tunicamycin on the Association of t-PA and BiP
Another way to examine unglycosylated forms of t-PA is to inhibit N-linked glycosylation by tunicamycin treatment. Immunofluorescence analysis showed that tunicamycin treatment of t-PAwt-producing cells results in accumulation of t-PA in the endoplasmic reticulum. When the AJ19 cell line is treated with 10 ug/ml tunicamycin for 1 hour the association of the unglycosylated t-PA with BiP is significantly increased compared to t-PAwt. t-PA-BiP complex is detected at the chase time point and there is some inhibition of secretion. Similar treatment of the t-PA3x-13 cell line did not produce an alteration in the amount of t-PA3x associated with BiP compared to untreated cells and the protein is secreted while a fraction of the intracellular t-PA remains associated with BiP. This pattern of protein processing in tunicamycin treated t-PA3x-13 cells looks similar to the untreated time course. This indicated that the influence of tunicamycin treatment on t-PAwt secretion was due to the absence of glycosylation on the molecule itself rather than an indirect effect of the tunicamycin.
It is striking that the t-PAwt treated with tunicamycin profile looks very much like that of t-PA3x at high expression levels. In both cases a similar proportion of the unglycosylated molecules are apparently not competent for efficient secretion and remain in an intracellular complex with BiP. At lower expression levels t-PA3x shows no significant association with BiP. t-PAwt at lower expression levels is affected to a lesser degree by tunicamycin treatment that the high producer cell line. Thus the association of unglycosylated t-PA with BiP is influenced by the intracellular levels of t-PA.
Unglycosylated t-PA appears as doublet in these experiments. t-PA is synthesized with a 12-15 amino acid long propeptide at the amino terminus of the protein (Pennica et al. Nature 1983). Most probably the higher molecular weight band represents the uncleaved pro-t-PA precursor form while the lower band represents the mature form which has been processed to remove the amino terminal propeptide. Since propeptide cleavage occurs in Golgi and post-Golgi compartments and BiP has been localized to the endoplasmic reticulum, only the pro-t-PA precursor form should be present in the same compartment as BiP. Consistent with this interpretations is the observation that only the higher molecular weight species of the doublet is found associated with BiP while only the lower molecular weight species is secreted.
COEXPRESSION OF GRP78 AND FVIII OR LA IN COS CELLS
A cDNA coding sequence for Chinese hamster GRP78 was placed in the expression vector pMT2 which is a derivative of p91023b and this expression vector (pMTGRP78) was cotransfected into COS cells with wt FVIII (pMT2VIII) or LA (pMT2LA) expression vectors to examine the consequences of overexpression of GRP78 on FVIII secretion. The transient expression of FVIII was monitored by assaying the conditioned medium for FVIII activity. Expression of GRP78 was detected by immunoprecipitation with the anti-BiP monoclonal. pMT2 may be obtained from pMT2-vWF (ATCC No. 67122) as described in detail below.
Coexpression of GRP78 and FVIII in COS cells consistently resulted in a 6-10 fold reduction in the levels of FVIII activity in the conditioned medium (Table 1, below). The effect of two different replicating vectors in the same cell is a decrease in the expression of both vectors. To compensate for this phenomenon, FVIII or LA vectors were always cotransfected with pCSF-1. pCSF-1 is an expression vector for GM-CSF which carries similar replication and transcription elements as pMT2 (Wong et al Science 1985). Coexpression of LA and GRP78 in COS cells resulted in a 2-3 fold reduction the levels of LA activity in the medium.
The degree of decrease of activity of LA and wt FVIII are consistent with the degree of association of FVIII and LA with BiP in CHO cells. The heavily glycosylated wt FVIII is more affected by GRP78 expression than LA in the transient COS system and also displays a stronger association with BiP in stable CHO cell lines. This data indicates that high levels of GRP78 can interfere with the secretion of FVIII and is suggestive that BiP and GRP78 are functionally and structurally similar.
EXAMPLES A. Preparation of GRP78 cDNA
The particular GRP78 cDNA used is a matter of choice. For example, one may use a Chinese hamster cDNA clone p3C5 obtained as described (Lee et al, 1983, J. Biol. Chem. 258:597). Alternatively a rat cDNA clone may be obtained, also as described (Munro & Pelham Cell 1986). Sequence analysis has shown that both of these clones encode the same protein identified as GRP78. At the amino acid level the rat and hamster proteins are 99.4% homologous. Cloning of a functional GRP78 cDNA may be effected using one or more oligonucleotides derived from the published sequence of GRP78 and purely conventional techniques as described by Lee et al. or Munro & Pelham, supra. Alternatively, a cloned rat cDNA may be obtained from Sean Munro, MRC Laboratory of Molecular Biology, Hills Road, Cambridge CB2 2QH, England.
B. Coexpression of Chinese Hamster GRP78 cDNA in Monkey Kidney COS Cells with F(VIII) or LA.
Chinese hamster GRP78 cDNA was placed into a mammalian expression vector pMT2. This vector is a derivative of p91023B and may be obtained by EcoRI digestion of pMT2-vWF, which has been deposited with the American Type Culture Collection under ATCC No. 67122. EcoRI digestion excises the cDNA insert present in pMT2-vWF, yielding pMT2 in linear form which can be ligated and used to transform E. coli HB101 or DH5 to ampicillin resistance. Plasmid pMT2 DNA can then be prepared by conventional methods. The 1962 nucleotide open reading frame encoding hamster GRP78 was excised by PstI and EcoRV digestion. The vector was prepared by EcoRI digestion, the EcoRI ends were filled in using Klenow fragment and then the vector was digested with PstI. The fragment from the hamster clone was ligated into the prepared pMT2 vector, although as indicated previously, other eucaryotic expression vectors may also be used. The resultant plasmid pMTGRP78 contains the adenovirus-VA genes, SV40 replication origin including enhancer, adenovirus major late promoter including tripartite leader and 5' donor splice site, 3' splice acceptor site, GRP78 cDNA insert, DHFR cDNA insert, SV40 early polyadenylation site and pBR322 sequences. pMTGRP78 was used to cotransfect COS-1 cells along with the FVIII expression vectors pMT2VIII or pMT2LA (Toole et al Proc. Natl. Acad. Sci. U.S.A. 1986) using the DEAE dextran procedure (Kaufman Proc. Natl. Acad. Sci. U.S.A. 1985). Conditioned medium was harvested at various times beginning 48 hours post-transfection and assayed for FVIII activity as described (Toole et al Nature 1984). The results of these experiments are summarized in Table I. Previous work has shown that cotransfection of two different expression vectors reduces the level of expression compared to transfection of a single vector. To compensate for this phenomenon the FVIII expression vectors were contransfected with pCSF-1, a previously described vector which expresses GM-CSF (Wong et al Science 1985). pCSF-1 is available from the American Type Culture Collection in E. coli MC1061 as ATCC 39754. The results in Table I show that coexpression of GRP78 and FVIII resulted in roughly six-ten fold reduction in the level of secreted FVIII activity and coexpression of GRP78 and LA resulted in a roughly two-three fold reduction compared to coexpression of FVIII or LA with GM-CSF. Analysis of extracts of COS cells cotransfected with pMTLA and pMTGRP78 or pMT2LA and pCSF-1 and subjected to a pulse/chase 35 S methionine label showed that in cells expressing pMTGRP78 more LA remained associated with BiP/GRP78 following the chase than was observed in the pCSF-1 cotransfected cells. These results indicated that overexpression of GRP78 prevented the secretion of FVIII by the intracellular association of FVIII and GRP78 and the retention of this complex in the cell. This suggested that otherwise secretion competent FVIII might be trapped inside cells expressing high levels of GRP78 and thus a decrease in GRP78 levels would facilitate the secretion of FVIII and other secretory proteins.
C. Coexpression of Chinese hamster GRP78 antisense cDNA with F(VIII) in Monkey Kidney COS cells.
Chinese hamster GRP78 cDNA was placed into pMT2 in the opposite orientation from that in the above-described expression vector. The 1962 nucleotide open reading frame was excised as follows. The hamster GRP78 clone was digested with EcoRV and a PstI linker was ligated to the blunt EcoRV end. The DNA was then cut with PstI to excise the 1962 bp open reading frame. The vector pMT2 was prepared by digestion with PstI. The fragment from the hamster was ligated into the PstI site of pMT2. The resultant plasmid pMTαB2 was identified by extensive restriction digest mapping to carry the GRP78 cDNA sequences such that the 3' end of the GRP78 cDNA ATCC No. 40387 was closest to the adenovirus major late promoter.
In this orientation transcripts expressed from the adenovirus major late promotor would contain sequence which is the complement of the GRP78 coding sequence. Such a RNA is commonly referred to as an antisense RNA. It has been reported that antisense RNA can interact intracellularly with its complementary sense mRNA and block the synthesis of the encoded protein (Kim and Wold Cell 1985).
pMTαB2 was used to cotransfect COS-1 cells along with the FVIII expression vector pMT2VIII using the DEAE dextran procedure. Conditioned medium was harvested at various times beginning 48 hours post-transfection and assayed for FVIII activity. The results of such an experiment are summarized in Table II. In this experiment coexpression of FVIII and antisense GRP78 sequences resulted in a 50% increase in FVIII activity in the conditioned medium compared to coexpression of FVIII and GM-CSF. This data indicates that the introduction of an antisense vector to decrease the intracellular level of GRP78 can result in increased level of FVIII secretion.
              TABLE I                                                     
______________________________________                                    
Cotransfection of FVIII and GRP78 Expression Vectors                      
in COS-1 Cells                                                            
               Chromogenic Activity                                       
               (milliunits/ml)                                            
______________________________________                                    
No DNA           0       0       0     0                                  
pMT2VIII/pCSF-1  67      93      30    30                                 
pMT2VIII/pMTGRP78                                                         
                 10      19      0     5                                  
pMT2LA/pCSF-1    290     --      536   436                                
pMT2LA/pMTGRP78  90      --      240   217                                
______________________________________                                    
 *Shown are the results of four separate experiments. The plasmids        
 indicated were cotransfected into COS1 cells and the conditioned medium  
 removed for assay by the Kabi Coatest F(VIII): C method.                 
              TABLE II                                                    
______________________________________                                    
Cotransfection of F(VIII) and Antisense GRP78                             
Expression Vectors in COS-1 Cells                                         
                Chromogenic Activity                                      
                (milliunits/ml)                                           
______________________________________                                    
pMTVIII/pCSF-1    90                                                      
pMTVIII/pMTαB2                                                      
                  135                                                     
No DNA            0                                                       
______________________________________                                    
 The plasmids indicated were cotransfected into COS1 cells and conditioned
 medium removed for an assay by the Kabi Coatest F(VIII): C method.       
DEVELOPMENT OF CHO CELL LINES WITH REDUCED BIP/GRP78 LEVELS AND FUSION WITH FVIII PRODUCING CELL LINES (1) Development of CHO cells with reduced BiP/GRP78 levels
Chinese hamster ovary (CHO) cell lines which are DHFR deficient, CHO- (DUKX-Bll), were grown in an alpha medium supplemented with 10 μg/ml each of thymidine, deoxyadenosine and adenosine. Cells were cotransfected with pMTαB2 (20 μg) and pSV2Neo (2 μg)(ATCC No. 37149) by the calcium phosphate coprecipitation procedure (Kaufman et al JMB 1982). pSV2Neo codes for resistance to the antibiotic G418 (P. Southern & Berg P. 1982 J. Mol. Appl. Genet. l 327-341). Forty-eight hours post-transfection the cells were plated in alpha medium supplemented with nucleosides as above and including 1 mg/ml of G418 in order to select for SV2Neo expression. pMTαB2 contains an intact DHFR coding region in the 3' region of the antisense GRP78 transcript. Thus G418 resistant transformants can be subsequently selected for DHFR expression from this mRNA. Growth in alpha media lacking nucleosides with 10% dialyzed fetal calf serum resulted in DHFR+ colonies. Five colonies were pooled to produce the A6B line. This line was then amplified by selection for growth in the presence of the folic acid analogue methotrexate at a concentration of 0.02 μM.
Following approximately 8 passages in 0.02 μM methetrexate the BiP/GRP78 level in A6B was compared to CHO DUKX by immunoprecipitation of radiolabeled cell extracts with anti-BiP monoclonal and analysis by SDS PAGE. A6B showed reduced levels of BiP/GRP78 compared to the original CHO line. In addition the level of antisense GRP78 RNA derived from pMTαB2 in these cells was determined by Northern analysis.
(3) Fusion of H9 with BiP/GRP78 reduced cell line
The A6B cell line was fused with an FVIII producing cell line H9 by standard polyethylene glycol procedure following treatment of A6B with DEPC to render them nonviable (W. E. Wright, Chap 5, The Selection of Heterokaryons and Cell Hybrids Using the Biochemical Inhibitors Iodoacetamide and Diethylpyrocarbonate in Techniques in Somatic Cell Genetics, Ed. J. W. Shay, Plenum Press). Two days following cell fusion the cells were plated in 1 μM methetrexate and 1 mg/ml G418. H9 grows in 1 μM methetrexate and G418 selects for the chromosome containing the antisense GRP78 sequences derived from A6B cells. After eleven days of growth twenty-two colonies were pooled to produce the cell line designated H9xA6B-9. Determination to the level of FVIII procoagulant activity secreted into the conditioned medium by H9xA6B-9 showed that this cell line yielded two-fold greater activity than the original H9 line.
CONCLUSIONS OF BIP/GRP78 ASSOCIATION STUDY
1. wt FVIII is associated with BiP and most of the FVIII which is never secreted remains associated with BiP. 20 out of 25 N-linked glycosylation sites are clustered in middle third of the FVIII protein.
2. LA, a deleted form of FVIII which has 18 of 20 clustered glycosylation sites removed, is more efficiently secreted than wt FVIII exhibits a transient association with BiP.
3. The association of LA with BiP can be significantly increased by treatment of cells with the N-linked glycosylation inhibitor tunicamycin.
4. VWF, a complex glycoprotein which is efficiently secreted by CHO cells, exhibits only a transient association with BiP. The 17 glycosylation sites on VWF are spaced along the molecule rather than clustered as on wt FVIII.
5. tPA exhibits only a slight transient association with BiP. However inhibition of N-linked glycosylation by tunicamycin results in the intracellular retention of some of the unglycosylated molecules in a complex with BiP.
6. tPA3x, an engineered mutant of t-PA which has had three potential N-linked glycosylation sites abolished by replacement of Asn with Gln exhibits only a slight association with BiP at low expression levels. However, at high expression levels a fraction of the unprocessed protein displays a stable association with BiP and is apparently not secreted effeciently. This behavior is similar th that observed for wt t-PA when glycosylation is inhibited.
7. Intracellular retention of unglycosylated tPA in a complex with BiP is dependent on expression level. tPA3x at low expression levels is not associated with BiP and is effeciently secreted. At 200-fold higher expression levels a significant proportion of tPA3x is associated with BiP. This intracellular retention is similar to that observed for the high producer wt tPA cell line, AJ19, when N-linked glycosylation is inhibited. In a low producing wt tPA cell line, H12B, the effect of inhibition of N-linked glycosylation is less pronounced than in cells such as AJ19. This suggests that unglycosylated tPA may aggregate when present at high concentrations in the ER leading to its association with BiP.
8. BiP may associate with improperly glycosylated or folded proteins in the endoplasmic reticulum and prevent their secretion. BiP probably functions to clear aggregated proteins from the endoplasmic reticulum in an analogous function to hsp70 in heat shocked nucleoli. The problem of protein aggregation or insolubility in the ER may be exacerbated by the high expression levels now attainable by recombinant DNA expressioin techniques and for some glycoproteins such as FVIII aggregation and consequent association with BiP may prove a barrier to high level secretion.
9. The 20 clustered glycosylation sites in the middle of wt FVIII may be inefficiently glycosylated resulting in aggregation of improperly folded molecules and stable assoc'n with BiP. It is also possible that this heavily glycosylated domain assumes a conformation which BiP recognizes as aberrant even if N-linked glycosylation is appropriate. In this situation secretion competent molecules may be trapped in a complex with BiP and reduced levels of BiP may result in higher levels of secretion.
10. Reduction of BiP levels in FVIII producing cell lines results in increased secretion of FVIII acitvity into the conditioned medium. Thsu CHO cell lines with reduced levels of BiP may be of utility in the expression of certain complex glycoproteins.
1. Bole, D. G., Hendershot, L. M., and Kearney J. F. (1986) Postranslational association of immunoglobulin heavy chain binding protein with nascent heavy chains in nonsecreting and secrating hybridomas. J. Cell Biol. 102:1558-1566.
2. Lewis, M. J. and Pelham H.R.B. (1985) Involvement of ATP in the nuclear and nucleolar functions of the 70Kd heat shock protein. EMBO J. 4:3137-3143.
3. Munro, S. and Pelham H.R.B. (1986) An hsp70-like protein in the ER:identity with the 78 Kd glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell 46:291-300.
4. Shiu, R. P., Pouyssegur, J., and Pasten I. (1977) Glucose deprivation accounts for the induction of two transfomation-sensitive membrane proteins in Rous sarcoma virus-transformed chick embryo fibfoblasts. Proc. Natl. Acad. Sci. U.S.A. 74:3840-3844.
5. Chappel, T. G., Welch, W. J., Schlossman, D. M., Palter, K. B., Schlesinger, M. J., and Rothman, J. E. (1986) Uncoating ATPase is a member of the 70- kD family of stress proteins. Cell 45:3-13.
6. Ungewickell, E. (1985) The 70 Kd mammalian heat shock proteins are structurally and functionally realated to the uncoating protein that releases clathrin triskelia from coated vesicles. EMBO J.4:3385-3391.
7. Pelham, H.R.B. (1986) Speculations on the functions of the major heat shock and glucose-regulated proteins. Cell 46:959-961.
8. Schlesinger, M. J. (1986) Heat shock proteins: the search for functions. J. Cell Biol. 103:321-325.
9. Williams D. B., Swiedler, S. J., and Hart, G. W. (1985) Intracellular transport of membrane glcoproteins: two closely related histocompatibility antigens differ in their rates of transit to the cell surface. J. Cell Biol. 101:725-734.
10. Lodish, H. F., Hong, N., Snider, M., Strous, G. J. (1983) Hepatoma secretory proteins migrate from rough endoplasmic reticulum to golgi at characteristic rates. Nature 304:80-83.
11. Fitting, T. and Kabat, D. (1982) Evidence for a glycoprotein signal involved in transport between subcellular organelles. J. Biol. Chem. 257:14011-14017.
12. Blobel, G. and Dobberstein, B. (1975) Transfer of proteins across membranes. II Reconstitution of functional rough microsomes from heterologous components. J. Cell Biol. 67:852-862.
13. Farquhar, M. G. (1986) Progress in unraveling pathways of golgi traffic. Ann. Rev. Cell Biol. 1:447-488.
14. Kornfeld, R. and Kornfeld, s. (1985) Assembly of asparigine-linked oligosaccharides. Ann. Rev. Biochem. 54:631-664
15. Walter, P., Gilmore, R. amd Blobel, G. (1984) Protein translocation across the endoplasmic reticulum. Cell 38:5-8.
16. Gething, M. J., McCammon, K., and Sambrook J. (1986) Expression of wild-type and mutant forms of influenza hemagglutinin: the role of folding in intracellular transport. Cell 46:939-950.
17. Sharma, S., Rogers, L., Brandsma, J., Gething, M. J., and Sambrook, J. (1985) SV40 T antigen and the exocytic pathway. EMBO J. 4:1479-1489.
18. Shiu, R. P. C., Pouyssegur, R., and Pasten, I. (1977) Glucose depletion accounts for the induction of two transformation-sensitive membrane proteins in Rous sarcoma virus-transformed chick embryo fibroblasts. Proc. Nat. Acad. Sci. U.S.A. 74, 3840-3844.
19. Haas, I. G. and Wable, m. (1983)Immunoglobulin heavy chain binding protein. Nature 306, 387-389.
20. Olden, K., Pratt, R. M., Jawosski, C., and Yamamda, K. M. (1979) Evidence for role of glycoprotein carbohydrates in membrane transport: specific inhibition by tunicamycin. Proc. Natl. Acad. Sci. U.S.A. 76, 791-795.
21. Pouyssegur, J., Shiu, R.P.C., and Pasten, I. (1977) Induction of two transformation-sensitive membrane polypeptides in normal fibriblasts by a block in glycoprotein synthesis or glucose deprivation. Cell 11, 941-947.
22. Wagner, D. D. and Marder, V. J. (1984) Biosynthesis of von Willebrand Protein by human endothelial cells: processing steps and their intracellular localization. J. Cell Biol. 99, 2123-2130.
23. Orci, L., Ravazzola, M., Amherdt, M., Madsen, O., Vassalli, J., and Perrelet, A. (1985) Direct identification of prohormone Conversion site in insulin-secreting cells. Cell 42, 671-681.
24. Pennica, D., Holmes, W., Kohr, W., Harkins, R. N., Vehar, G. A., Ward, C. A., Bennett, W. F., Yelverton, E., Seeburg, P. H., Heyneker, H., Goeddel, D. V., and Collen, D. (1983) Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301, 214-221.
25. Kaufman, R. J., Wasley, L. C., Spiliotes, A. J., Gossels, S. D., Latt, S., A., Larsen, G. R., and Kay, R. M. (1985) Coamplification and coexpression of human tissue-type plasminogen activator and murine dihydrofolate reductase sequences in Chinese hamster ovary cells. Mol. Cell Biol. 5, 1750-1759.
26. Toole, J. J., Pittman, D. D., Orr, E. C., Murtha, P., Wasley, L. C., and Kaufman, R. J. (1986) A large region (95 kDa) of human factor VIII is dispensible for in vitro procoagulant activity. Proc. Natl. Acad. Sci. U.S.A. 83, 5939-5942.
27. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
28. Toole, J. J., Knopf, J. L., Wozney, J. M., Sultzman, L. A., Buecker, J. L., Pittman, D. D., Kaufman, R. J., Brown, E., Shoemaker, C., Orr, E. C., Amphlett, G. W., Foster, W. B., Coe, M. L., Knutson, G. J., Fass, D. N., and Hewick, R. M. (1984) Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312, 342-347.
29. Gibson, R., Schlesinger, S., and Kornfeld, S. (1979) The nonglycosylated glycoprotein of vesicular stomatitus virus is temperature-sensitive and undergoes intracellular aggregation at elevated temperatures. J. Biol. Chem. 254, 3600-3607.
30. Gibson, R., Kornfeld, S., and Schlesinger, S. (1981) The effect of oligosaccharide chains of different sizes on the maturation and physical properties of the G protein of vesicular stomatitus virus. J. Biol. Chem. 256, 456-462.
31. Takasuki, A., Kohno, K., amd Tamura, G. (1975) Inhibition of biosynthesis of polyisoprenol sugars in chick embryo microsomes by tunicamycin. Agric. Biol. Chem. 39, 2089-2091.
32. Bonthron, D. T., Handin, R. I., Kaufman, R. J., Wasley, L. C., Orr, E. C., Mitsock, L. M., Ewenstein, B., Loscalzo, J., Ginsburg, D., Orkin, S. H. (1986) Structure of pre-pro-von Willebrand factor and its expression in heterologous cells. Nature 324, 270-273.
33. Pohl, G., Kallstrom, M., Bergsdorf, N., Wallen, P., and Jornvall, H. (1984) Tissue plasminogen activator: peptide analysis confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences. Biochemistry 23, 3701-3707.

Claims (7)

What is claimed is:
1. An anti-sense expression vector capable of directing the transcription in a host cell of mRNA complementary to mRNA encoding the host cell's GRP78, said vector comprising a DNA sequence encoding host cell GRP78 peptide sequence operatively linked to an expression control sequence in reverse orientation such that transcription of the DNA produces the anti-sense mRNA.
2. A eucaryotic host cell for expressing a protein heterologous to the cell which comprises a host cell transformed with a vector of claim 1.
3. A yeast, fungal, insect, plant or mammalian host cell of claim 2.
4. A host cell of claim 2 which is additionally transformed with a vector capable of directing the expression of a protein heterologous to the cell.
5. A host cell of claim 4, wherein the protein heterologous to the cell is a factor VIII protein.
6. A method for producing a protein heterologous to a host cell by culturing a host cell transformed with a vector capable of directing the expression of the heterologous protein, the improvement comprising culturing a transformed host cell of claim 4 as the transformed host cell.
7. A method for producing a factor VIII protein which comprises culturing the improved host cell of claim 5 and recovering from the culture medium the Factor VIII protein so produced and secreted.
US07/010,351 1986-11-14 1987-02-03 Eucaryotic expression system Expired - Lifetime US4912040A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US07/010,351 US4912040A (en) 1986-11-14 1987-02-03 Eucaryotic expression system
CA000551771A CA1297436C (en) 1986-11-14 1987-11-13 Eucaryotic expression system
ES8703256A ES2013324A6 (en) 1986-11-14 1987-11-13 Eucaryotic expression system.
PCT/US1987/002971 WO1988003558A1 (en) 1986-11-14 1987-11-13 Eucaryotic expression system
AU11002/88A AU1100288A (en) 1986-11-14 1987-11-13 Eucaryotic expression system
DE88900621T DE3789017D1 (en) 1986-11-14 1987-11-13 Eucaryotisches expressionssystem.
JP63501181A JPH01501363A (en) 1986-11-14 1987-11-13 Eukaryotic expression system
EP88900621A EP0289597B1 (en) 1986-11-14 1988-05-26 Eucaryotic expression system
AT88900621T ATE101195T1 (en) 1986-11-14 1988-05-26 EUCARYOTIC EXPRESSION SYSTEM.
KR1019880700824A KR890700164A (en) 1986-11-14 1988-07-14 Eukaryotic cell expression system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93138186A 1986-11-14 1986-11-14
US07/010,351 US4912040A (en) 1986-11-14 1987-02-03 Eucaryotic expression system

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US93138186A Continuation-In-Part 1986-11-14 1986-11-14

Publications (1)

Publication Number Publication Date
US4912040A true US4912040A (en) 1990-03-27

Family

ID=26681064

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/010,351 Expired - Lifetime US4912040A (en) 1986-11-14 1987-02-03 Eucaryotic expression system

Country Status (9)

Country Link
US (1) US4912040A (en)
EP (1) EP0289597B1 (en)
JP (1) JPH01501363A (en)
KR (1) KR890700164A (en)
AU (1) AU1100288A (en)
CA (1) CA1297436C (en)
DE (1) DE3789017D1 (en)
ES (1) ES2013324A6 (en)
WO (1) WO1988003558A1 (en)

Cited By (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) * 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5272065A (en) * 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5340739A (en) * 1988-07-13 1994-08-23 Brigham & Women's Hospital Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof
EP0785273A1 (en) 1990-11-26 1997-07-23 Genetics Institute, Inc. Paired basic amino acid converting enzyme and DNA sequence encoding it
US5928915A (en) * 1993-05-17 1999-07-27 Genentech, Inc. CHO cell sialidase by recombinant DNA technology
US6399377B1 (en) 1995-11-27 2002-06-04 Yves Mory Use of anti-sense sequences to increase responsiveness to gene amplification
US6472142B1 (en) * 1997-12-03 2002-10-29 Leadd B.V. Methods and means for inducing apoptosis by interfering with Bip-like proteins
US20030035301A1 (en) * 2001-06-26 2003-02-20 Allan Gardiner Multiple wavelength illuminator
US6562588B2 (en) * 1993-05-17 2003-05-13 Genentech, Inc. Sialidase and recombinant cell lines
US20030211100A1 (en) * 2001-11-09 2003-11-13 Vahe Bedian Antibodies to CD40
US20040023313A1 (en) * 2002-04-05 2004-02-05 Boyle William J Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US20040086503A1 (en) * 2001-01-05 2004-05-06 Cohen Bruce D. Antibodies to insulin-like growth factor I receptor
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US20040176290A1 (en) * 2001-07-18 2004-09-09 Renata Pasqualini Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
WO2004084823A2 (en) 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
US20050003466A1 (en) * 2000-09-08 2005-01-06 Wadih Arap Aminopeptidase a (APA) targeting peptides for the treatment of cancer
US20050014931A1 (en) * 2001-05-16 2005-01-20 Pirofski Liise-Anne Human antipneumococcal antibodies from non-human animals
WO2005010046A1 (en) 2003-06-27 2005-02-03 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
WO2005016111A2 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
US20050054019A1 (en) * 2003-08-04 2005-03-10 Michaud Neil R. Antibodies to c-Met
US20050059113A1 (en) * 2003-09-10 2005-03-17 Vahe Bedian Antibodies to M-CSF
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
WO2005092926A2 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
US20050232917A1 (en) * 2004-01-09 2005-10-20 Nicholas Pullen Antibodies to MAdCAM
US20050287136A1 (en) * 1998-12-23 2005-12-29 Hanson Douglas C Human monoclonal antibodies to CTLA-4
US20060002929A1 (en) * 2004-03-23 2006-01-05 Khare Sanjay D Monoclonal antibodies
US20060018910A1 (en) * 2004-07-16 2006-01-26 Pfizer Inc Combination treatment for non-hematologic malignancies
US20060094672A1 (en) * 2001-09-07 2006-05-04 Renata Pasqualini Compositions and methods of use of targeting peptides against placenta and adipose tissues
WO2006052975A2 (en) 2004-11-08 2006-05-18 Schering Corporation Tumor association of mdl-1 and methods
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
WO2006068975A2 (en) 2004-12-20 2006-06-29 Abgenix, Inc. Binding proteins specific for human matriptase
US20060239968A1 (en) * 2002-08-30 2006-10-26 Wadih Arap Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20060263354A1 (en) * 2005-04-25 2006-11-23 Amgen Fremont Inc. Antibodies to myostatin
US20070065444A1 (en) * 2005-09-07 2007-03-22 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
WO2007059082A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
WO2007068895A1 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
WO2007077028A2 (en) 2005-12-30 2007-07-12 U3 Pharma Ag Antibodies directed to her-3 and uses thereof
US20080009607A1 (en) * 2006-05-22 2008-01-10 California Institute Of Technology Antibodies to sulfated carbohydrates
EP1878746A2 (en) 1997-05-05 2008-01-16 Amgen Fremont Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2008017126A1 (en) 2006-08-11 2008-02-14 Csl Limited Treatment of pulmonary disease conditions
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL
WO2008073300A2 (en) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
US20080166352A1 (en) * 2005-07-18 2008-07-10 Amgen Inc. Human anti-B7RP1 Neutralizing Antibodies
US20080233122A1 (en) * 1998-12-23 2008-09-25 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
WO2009040134A1 (en) 2007-09-26 2009-04-02 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
WO2009052588A1 (en) 2007-10-26 2009-04-30 Csl Limited Cytokine muteins
WO2009064944A2 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
US20090252746A1 (en) * 2002-10-14 2009-10-08 Abbott Laboratories Erythropoietin receptor binding antibodies
EP2112166A2 (en) 1998-12-23 2009-10-28 Pfizer Inc. Human monoclonal antibodies to CTLA-4
US20100055033A1 (en) * 2006-04-07 2010-03-04 The Government Of The United States Of America As Represented By The Secretary Antibody compositions and methods for treatment of neoplastic disease
US20100068135A1 (en) * 2005-08-08 2010-03-18 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US20100076184A1 (en) * 1998-07-22 2010-03-25 Vanderbilt University Gbs toxin receptor
WO2010067308A2 (en) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
WO2010075238A1 (en) 2008-12-23 2010-07-01 Amgen Inc. Human cgrp receptor binding proteins
US20100172864A1 (en) * 2001-09-07 2010-07-08 Wadih Arap Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
EP2213685A1 (en) 2002-09-06 2010-08-04 Amgen Inc. Therapeutic anti-IL-1R1 monoclonal antibody
EP2236519A1 (en) 2007-09-18 2010-10-06 Amgen, Inc Human GM-CSF antigen binding proteins
WO2011014438A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
WO2011017294A1 (en) 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
US20110059041A1 (en) * 2003-09-12 2011-03-10 Alemseged Truneh Vaccine for treatment and prevention of herpes simplex virus infection
EP2298811A2 (en) 2002-10-16 2011-03-23 Amgen Inc. Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors
WO2011032204A1 (en) 2009-09-15 2011-03-24 Csl Limited Treatment of neurological conditions
EP2311491A1 (en) 2005-03-08 2011-04-20 Pharmacia & Upjohn Company LLC Composition comprising an antibody against macrophage colony-stimulating factor (M-CSF) and a chelating agent
WO2011049758A1 (en) 2009-10-09 2011-04-28 Amgen Inc. Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
EP2316922A1 (en) 2002-05-24 2011-05-04 Schering Corporation Neutralizing human anti-IGFR antibody
WO2011056600A1 (en) 2009-10-26 2011-05-12 Amgen Inc. Human il-23 antigen binding proteins
WO2011060206A2 (en) 2009-11-13 2011-05-19 U3 Pharma Gmbh Material and methods for treating or preventing her-3 associated diseases
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
WO2011071783A1 (en) 2009-12-07 2011-06-16 Amgen Inc. Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
EP2336177A1 (en) 2004-08-04 2011-06-22 Amgen, Inc Antibodies to DKK-1
EP2341067A1 (en) 2003-07-18 2011-07-06 Amgen, Inc Specific binding agents to hepatocyte growth factor
EP2357202A1 (en) 2006-04-10 2011-08-17 AstraZeneca AB Targeted binding agents directed to Upar and uses thereof
EP2361933A2 (en) 2005-01-26 2011-08-31 Amgen Fremont Inc. Antibodies against interleukin-1 beta
US20110217316A1 (en) * 1998-07-22 2011-09-08 Vanderbilt University GBS Toxin Receptor Compositions and Methods of Use
EP2366715A2 (en) 2005-11-14 2011-09-21 Amgen Inc. Rankl Antibody-PTH/PTHRP Chimeric Molecules
EP2371865A2 (en) 2006-04-07 2011-10-05 Warner Chilcott Company, LLC Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof
EP2374816A1 (en) 2010-04-07 2011-10-12 Humalys Binding molecules against Chikungunya virus and uses thereof
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
EP2404616A2 (en) 2005-12-13 2012-01-11 AstraZeneca AB Binding proteins specific for insulin-like growth factors and uses thereof
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
WO2012018404A2 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
EP2420514A1 (en) 2006-08-03 2012-02-22 MedImmune Limited Targeted binding agents directed to PDGFR-alpha and uses thereof
WO2012035518A1 (en) 2010-09-17 2012-03-22 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
EP2444420A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
WO2012058393A2 (en) 2010-10-27 2012-05-03 Amgen Inc. Dkk1 antibodies and methods of use
EP2457586A1 (en) 2003-06-27 2012-05-30 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
EP2476427A2 (en) 2004-08-02 2012-07-18 Zenyth Operations PTY. Ltd. A method of treating cancer comprising a VEGF-B antagonist
WO2012102679A1 (en) 2011-01-24 2012-08-02 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
WO2012118903A2 (en) 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
WO2012138997A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
EP2511301A2 (en) 2006-08-04 2012-10-17 Medimmune Limited Human antibodies to ERBB2
WO2012154999A1 (en) 2011-05-10 2012-11-15 Amgen Inc. Methods of treating or preventing cholesterol related disorders
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
EP2573111A1 (en) 2006-04-20 2013-03-27 Amgen Inc. GLP-1 compounds
WO2013056233A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Treatment of ocular disease
EP2589610A1 (en) 2007-08-21 2013-05-08 Amgen, Inc Human c-fms antigen binding proteins
WO2013068902A1 (en) 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
EP2594590A1 (en) 2007-12-14 2013-05-22 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
WO2013075048A1 (en) 2011-11-16 2013-05-23 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
WO2013120012A2 (en) 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
WO2013163377A1 (en) 2012-04-27 2013-10-31 Novo Nordisk A/S Human cd30 ligand antigen binding proteins
WO2013166448A1 (en) 2012-05-03 2013-11-07 Amgen Inc. Stable formulations containing anti-pcsk9 antibodies
WO2013186719A1 (en) 2012-06-15 2013-12-19 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
WO2013188448A2 (en) 2012-06-11 2013-12-19 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
WO2014087299A1 (en) 2012-12-07 2014-06-12 Pfizer Inc. Engineered monomeric antibody fragments
WO2014089335A2 (en) 2012-12-07 2014-06-12 Amgen Inc. Bcma antigen binding proteins
WO2014100079A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Antibodies that bind to human programmed death ligand 1 (pd-l1)
WO2014130879A2 (en) 2013-02-22 2014-08-28 Stem Centrx, Inc. Novel antibody conjugates and uses thereof
WO2014144553A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
WO2014144632A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Human pac1 antibodies
WO2014159764A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
WO2014165422A1 (en) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
US8912149B1 (en) 2007-11-28 2014-12-16 California Institute Of Technology Glycosaminoglycan mimetics
WO2014209384A1 (en) 2013-06-28 2014-12-31 Amgen Inc. Methods for treating homozygous familial hypercholesterolema
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
EP2927244A1 (en) 2008-09-19 2015-10-07 MedImmune, LLC Antibodies directed to DLL4 and uses thereof
DE202008018562U1 (en) 2007-08-23 2015-11-02 Amgen Inc. Antigen-binding Proteins Against Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
WO2015173756A2 (en) 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
WO2016028672A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
WO2016028656A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-tigit antibodies
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
WO2016042412A1 (en) 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
US9464139B2 (en) 2013-08-30 2016-10-11 Amgen Inc. GITR antigen binding proteins and methods of use thereof
WO2016171742A1 (en) 2015-04-24 2016-10-27 Amgen Inc. Methods for treating or preventing migraine headache
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
WO2017075124A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Antibody neutralizing human respiratory syncytial virus
WO2017079215A1 (en) 2015-11-03 2017-05-11 Glycomimetics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
WO2017079273A2 (en) 2015-11-03 2017-05-11 Glycomimetics, Inc. Antibodies for targeting cancer stem cells and treating aggressive cancers
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
EP3279215A1 (en) 2009-11-24 2018-02-07 MedImmune Limited Targeted binding agents against b7-h1
WO2018058022A1 (en) 2016-09-26 2018-03-29 Merck Sharp & Dohme Corp. Anti-cd27 antibodies
WO2018069500A2 (en) 2016-10-13 2018-04-19 Symphogen A/S Anti-lag-3 antibodies and compositions
WO2018091661A1 (en) 2016-11-18 2018-05-24 Symphogen A/S Anti-pd-1 antibodies and compositions
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
WO2018185232A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-1, tim-3, and lag-3
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
WO2018194496A2 (en) 2017-04-17 2018-10-25 Закрытое Акционерное Общество "Биокад" Monoclonal antibody to pd-l1
WO2018222770A1 (en) 2017-05-31 2018-12-06 Amgen Inc. Anti-jagged1 antigen binding proteins
US10150811B2 (en) 2011-10-13 2018-12-11 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
WO2018237097A1 (en) 2017-06-20 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
WO2019014572A1 (en) 2017-07-14 2019-01-17 Pfizer, Inc. Antibodies to madcam
WO2019028382A1 (en) 2017-08-04 2019-02-07 Amgen Inc. Method of conjugation of cys-mabs
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
WO2019070164A1 (en) 2017-10-03 2019-04-11 Закрытое Акционерное Общество "Биокад" MONOCLONAL ANTIBODY TO IL-5Rα
US10294303B2 (en) 2015-12-23 2019-05-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
WO2019108806A1 (en) 2017-11-29 2019-06-06 Board Of Regents Of The University Of Texas System Compositions and methods for cancer therapy
WO2019147831A1 (en) 2018-01-26 2019-08-01 Regeneron Pharmaceuticals, Inc. Anti-tmprss2 antibodies and antigen-binding fragments
WO2019152642A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US10421824B2 (en) 2013-03-13 2019-09-24 Amgen Inc. Proteins specific for BAFF and B7RP1
US10421823B2 (en) 2013-03-13 2019-09-24 Amgen Inc. Proteins specific for BAFF and B7RP1 and uses thereof
WO2019190931A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Anti-pfrh5 antibodies and antigen-binding fragments thereof
EP3575316A1 (en) 2014-08-27 2019-12-04 Amgen, Inc Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
WO2020018503A2 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
WO2020055293A1 (en) 2018-09-14 2020-03-19 Закрытое Акционерное Общество "Биокад" Pacas9 nuclease
WO2020091634A1 (en) 2018-10-31 2020-05-07 Закрытое Акционерное Общество "Биокад" Monoclonal antibody that specifically binds to cd20
WO2020160242A1 (en) 2019-02-01 2020-08-06 Regeneron Pharmaceuticals, Inc. Anti-il2 receptor gamma antigen-binding proteins
WO2020198009A1 (en) 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. EGFR x CD28 MULTISPECIFIC ANTIBODIES
WO2020218951A2 (en) 2019-04-23 2020-10-29 Закрытое Акционерное Общество "Биокад" Monoclonal antibody that binds specifically to gitr
WO2021001458A1 (en) 2019-07-01 2021-01-07 Tonix Pharma Holdings Limited Anti-cd154 antibodies and uses thereof
EP3763388A1 (en) 2011-02-18 2021-01-13 AbbVie Stemcentrx LLC Novel modulators and methods of use
US10905772B2 (en) 2017-01-17 2021-02-02 Amgen Inc. Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)
WO2021021676A1 (en) 2019-07-26 2021-02-04 Amgen Inc. Anti-il13 antigen binding proteins
WO2021044005A1 (en) 2019-09-06 2021-03-11 Symphogen A/S Anti-cd73 antibodies
WO2021054867A1 (en) 2019-09-19 2021-03-25 Закрытое Акционерное Общество "Биокад" IMMUNOCYTOKINE COMPRISING HETERODIMERIC PROTEIN COMPLEX BASED ON IL-15/IL-15Rα
WO2021091906A1 (en) 2019-11-04 2021-05-14 Amgen Inc. Methods for treating leukemia
WO2021113591A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Vegf mini-traps and methods of use thereof
WO2021163076A1 (en) 2020-02-10 2021-08-19 Regeneron Pharmaceuticals, Inc. ANTl-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
EP3889177A1 (en) 2020-04-02 2021-10-06 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
WO2021219871A2 (en) 2020-04-30 2021-11-04 Aduro Biotech Holdings, Europe B.V. Anti-cd103 antibodies
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
WO2021242815A1 (en) 2020-05-26 2021-12-02 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
IT202000015754A1 (en) 2020-06-30 2021-12-30 Fond Toscana Life Sciences ANTIBODIES TO CORONAVIRUS
WO2022003530A1 (en) 2020-06-30 2022-01-06 Fondazione Toscana Life Sciences Neutralizing antibodies to sars coronavirus-2
WO2022020636A2 (en) 2020-07-24 2022-01-27 Amgen Inc. Immunogens derived from sars-cov2 spike protein
WO2022023292A2 (en) 2020-07-31 2022-02-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Corona virus spike protein-targeting antibodies and use thereof
EP3978531A1 (en) 2016-04-12 2022-04-06 Symphogen A/S Anti-tim-3 antibodies and compositions
US11352443B2 (en) 2016-11-09 2022-06-07 North Carolina State University Treatment of allergic diseases with chimeric protein
IT202100003470A1 (en) 2021-02-16 2022-08-16 Fond Toscana Life Sciences VACCINES AGAINST SARS-COV-2
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
US11453717B2 (en) 2016-04-29 2022-09-27 Joint Stock Company “Biocad” Trispecific antibodies against IL-17A, IL-17F and other pro-inflammatory molecule
EP4105235A1 (en) 2015-10-02 2022-12-21 Symphogen A/S Anti-pd-1 antibodies and compositions
WO2023287875A1 (en) 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
WO2023155902A1 (en) 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
WO2023173132A1 (en) 2022-03-11 2023-09-14 Regeneron Pharmaceuticals, Inc. Anti-glp1r antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
EP4248976A2 (en) 2007-08-23 2023-09-27 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2023180533A1 (en) 2022-03-25 2023-09-28 Les Laboratoires Servier Anti-gal3 antibodies and compositions
US11840567B2 (en) 2017-10-03 2023-12-12 Joint Stock Company “Biocad” Bispecific antibodies with specific binding to CD47 and PD-L1
WO2024026470A2 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Anti-tfr:payload fusions and methods of use thereof
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024050526A1 (en) 2022-09-02 2024-03-07 Biomarin Pharmaceutical Inc. Compositions and methods for treating long qt syndrome

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5965405A (en) * 1988-04-16 1999-10-12 Celltech Limited Method for producing Fv fragments in eukaryotic cells
US5665550A (en) * 1990-10-19 1997-09-09 Board Of Trustees Of The University Of Illinois-Urbana Genes and genetic elements associated with sensitivity to chemotherapeutic drugs
US5217889A (en) * 1990-10-19 1993-06-08 Roninson Igor B Methods and applications for efficient genetic suppressor elements
US5942389A (en) 1990-10-19 1999-08-24 Board Of Trustees Of The University Of Illinois Genes and genetic elements associated with sensitivity to cisplatin
US5866327A (en) * 1990-10-19 1999-02-02 Board Of Trustees Of The University Of Illinois Association of kinensin with sensitivity to chemotherapeutic drugs
US6268134B1 (en) 1993-09-07 2001-07-31 Board Of Trustees Of University Of Il Method and applications for efficient genetic suppressor elements
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
WO1996028966A1 (en) * 1995-03-17 1996-09-26 Chihiro Koike Transformant of nonprimatial mammal having serotype of advanced primate expressed by foreign gene transduction and process for producing the same
ZA959429B (en) * 1995-11-07 1996-07-11 Interpharm Lab Ltd Use of anti-sense sequences to increase responsiveness to gene amplification
EP1754718B1 (en) 1996-04-24 2011-03-23 The Regents Of The University Of Michigan Inactivation resistant factor VIII
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
DE69902639T2 (en) 1998-03-12 2003-04-24 Inst Genetics Llc IMPROVED METHOD FOR PRODUCING FACTOR VIII
WO2002060951A2 (en) 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
US20050143291A1 (en) * 2003-10-27 2005-06-30 Lee Amy S. Methods and compositions for modulating apoptosis
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2656558A1 (en) 2006-06-30 2008-01-10 The Regents Of The University Of Michigan Method of producing factor viii proteins by recombinant methods
EP3222287A1 (en) 2009-08-24 2017-09-27 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
EP2506868B1 (en) 2009-12-06 2017-11-15 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
EP3527218A1 (en) 2011-06-10 2019-08-21 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
PT3513804T (en) 2011-07-08 2022-06-02 Bioverativ Therapeutics Inc Factor viii chimeric and hybrid polypeptides, and methods of use thereof
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
JP6234378B2 (en) 2012-01-12 2017-11-22 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. Method for reducing immunogenicity against factor VIII in an individual undergoing factor VIII therapy
LT2804623T (en) 2012-01-12 2019-12-10 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof
ES2771208T3 (en) 2012-02-15 2020-07-06 Bioverativ Therapeutics Inc Factor VIII compositions and methods of preparation and use thereof
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
EA201792485A3 (en) 2012-07-11 2019-03-29 Амуникс Оперэйтинг Инк. COMPLEX OF FACTOR VIII WITH XTEN AND PROTEIN FACTOR VILLEBRAND VON AND ITS APPLICATION (OPTIONS)
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc Methods of using fviii polypeptide
EP2968477B1 (en) 2013-03-15 2019-12-04 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
EP3875106A1 (en) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
EP4332839A2 (en) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
IL246476B (en) 2014-01-10 2022-06-01 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
KR20180029262A (en) 2015-08-03 2018-03-20 바이오버라티브 테라퓨틱스 인크. Factor IX fusion proteins and methods for their manufacture and use
KR20210020030A (en) 2018-05-18 2021-02-23 바이오버라티브 테라퓨틱스 인크. How to treat hemophilia A
CN114096659A (en) * 2019-06-10 2022-02-25 Cho普拉斯公司 Cell lines for high level production of protein-based drugs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Attenello et al.; Science 226: 187 (1984). *
Izant et al.; Science 229: 346 (1985). *
Lee et al.: J. Biolo. Chem. 258: 597 (1983). *
Lin et al.: Mol. Cell. Biol. 6: 1235 (1986). *
Toole et al.; Nature 312: 342 (1984). *

Cited By (426)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190931A (en) * 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) * 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5272065A (en) * 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5340739A (en) * 1988-07-13 1994-08-23 Brigham & Women's Hospital Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof
EP0785273A1 (en) 1990-11-26 1997-07-23 Genetics Institute, Inc. Paired basic amino acid converting enzyme and DNA sequence encoding it
US6562588B2 (en) * 1993-05-17 2003-05-13 Genentech, Inc. Sialidase and recombinant cell lines
US6916916B2 (en) 1993-05-17 2005-07-12 Genentech, Inc. Sialidase and recombinant cell lines
US20030148493A1 (en) * 1993-05-17 2003-08-07 Genentech, Inc. Sialidase and recombinant cell lines
US5928915A (en) * 1993-05-17 1999-07-27 Genentech, Inc. CHO cell sialidase by recombinant DNA technology
US6399377B1 (en) 1995-11-27 2002-06-04 Yves Mory Use of anti-sense sequences to increase responsiveness to gene amplification
EP1878746A2 (en) 1997-05-05 2008-01-16 Amgen Fremont Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP2332993A1 (en) 1997-05-05 2011-06-15 Amgen Fremont Inc. Human monoclonal antibody to the human epidermal growth factor receptor
US6472142B1 (en) * 1997-12-03 2002-10-29 Leadd B.V. Methods and means for inducing apoptosis by interfering with Bip-like proteins
US20110217316A1 (en) * 1998-07-22 2011-09-08 Vanderbilt University GBS Toxin Receptor Compositions and Methods of Use
US8609614B2 (en) 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
US20100076184A1 (en) * 1998-07-22 2010-03-25 Vanderbilt University Gbs toxin receptor
US7807797B2 (en) 1998-12-23 2010-10-05 Amgen Fremont Inc. Human monoclonal antibodies to CTLA-4
EP3553085A1 (en) 1998-12-23 2019-10-16 Pfizer Inc Human momoclonal antibodies to ctla-4
US8143379B2 (en) 1998-12-23 2012-03-27 Amgen Fremont Inc. Human monoclonal antibodies to CTLA-4
US9963508B2 (en) 1998-12-23 2018-05-08 Amgen Fremont Inc. Human monoclonal antibodies to CTLA-4
US7411057B2 (en) 1998-12-23 2008-08-12 Amgen Fremont Inc. Nucleic acids encoding human monoclonal antibodies to CTLA-4
US20050287136A1 (en) * 1998-12-23 2005-12-29 Hanson Douglas C Human monoclonal antibodies to CTLA-4
US20080233116A1 (en) * 1998-12-23 2008-09-25 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7824679B2 (en) 1998-12-23 2010-11-02 Amgen Fremont Inc. Human monoclonal antibodies to CTLA-4
EP2112166A2 (en) 1998-12-23 2009-10-28 Pfizer Inc. Human monoclonal antibodies to CTLA-4
US8883984B2 (en) 1998-12-23 2014-11-11 Amgen Fremont Inc. Human monoclonal antibodies to CTLA-4
US7132281B2 (en) 1998-12-23 2006-11-07 Amgen Fremont Inc. Methods and host cells for producing human monoclonal antibodies to CTLA-4
US20080233122A1 (en) * 1998-12-23 2008-09-25 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US8491895B2 (en) 1998-12-23 2013-07-23 Amgen Fremont Inc. Methods of treating cancer with human monoclonal antibodies to CTLA-4
US8252764B2 (en) 2000-09-08 2012-08-28 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7951362B2 (en) 2000-09-08 2011-05-31 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US8710017B2 (en) 2000-09-08 2014-04-29 Board Of Regents, The University Of Texas Systems Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20080124277A1 (en) * 2000-09-08 2008-05-29 Wadih Arap Human and Mouse Targeting Peptides Identified by Phage Display
US20050003466A1 (en) * 2000-09-08 2005-01-06 Wadih Arap Aminopeptidase a (APA) targeting peptides for the treatment of cancer
US20090104117A1 (en) * 2000-09-08 2009-04-23 Renata Pasqualini Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7914780B1 (en) 2000-09-08 2011-03-29 Board Of Regents, The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US8067377B2 (en) 2000-09-08 2011-11-29 The Board Of Regents Of The University Of Texas Systems Peptide compositions for targeting adipose tissue
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US8846859B2 (en) 2000-09-08 2014-09-30 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US20050281812A1 (en) * 2001-01-05 2005-12-22 Pfizer Inc Antibodies to insulin-like growth factor I receptor
US7037498B2 (en) 2001-01-05 2006-05-02 Abgenix, Inc. Antibodies to insulin-like growth factor I receptor
US20050244408A1 (en) * 2001-01-05 2005-11-03 Cohen Bruce D Antibodies to insulin-like growth factor I receptor
US7700742B2 (en) 2001-01-05 2010-04-20 Amgen Fremont Antibodies to insulin-like growth factor I receptor
US8642037B2 (en) 2001-01-05 2014-02-04 Amgen Fremont Inc. Antibodies to insulin-like growth factor I receptor
EP2796468A2 (en) 2001-01-05 2014-10-29 Pfizer Inc Antibodies to insulin-like growth factor I receptor
EP2194067A2 (en) 2001-01-05 2010-06-09 Pfizer Inc. Antibodies to insulin-like growth factor I receptor (IGF-IR)
US20040086503A1 (en) * 2001-01-05 2004-05-06 Cohen Bruce D. Antibodies to insulin-like growth factor I receptor
US7982024B2 (en) 2001-01-05 2011-07-19 Amgen Fremont Inc. Antibodies to insulin-like growth factor I receptor
US9234041B2 (en) 2001-01-05 2016-01-12 Pfizer Inc. Antibodies to insulin-like growth factor I receptor
US7815907B2 (en) 2001-01-05 2010-10-19 Amgen Fremont Inc. Antibodies to insulin-like growth factor I receptor
US20050014931A1 (en) * 2001-05-16 2005-01-20 Pirofski Liise-Anne Human antipneumococcal antibodies from non-human animals
US7078492B2 (en) 2001-05-16 2006-07-18 Abgenix, Inc. Human antipneumococcal antibodies from non-human animals
US20060258848A1 (en) * 2001-05-16 2006-11-16 Pirofski Liise-Anne Human antipneumococcal antibodies from non-human animals
US20030035301A1 (en) * 2001-06-26 2003-02-20 Allan Gardiner Multiple wavelength illuminator
EP3492100A1 (en) 2001-06-26 2019-06-05 Amgen Inc. Antibodies to opgl
US7364736B2 (en) 2001-06-26 2008-04-29 Amgen Inc. Antibodies to OPGL
EP2087908A1 (en) 2001-06-26 2009-08-12 Amgen, Inc. Antibodies to opgl
US20040176290A1 (en) * 2001-07-18 2004-09-09 Renata Pasqualini Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20100172864A1 (en) * 2001-09-07 2010-07-08 Wadih Arap Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US20060094672A1 (en) * 2001-09-07 2006-05-04 Renata Pasqualini Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20090169563A1 (en) * 2001-11-09 2009-07-02 Abgenix, Inc. Antibodies to CD40
US7563442B2 (en) 2001-11-09 2009-07-21 Abgenix, Inc. Antibodies to CD40 and methods of treating cancer and enhancing immune responses
US20100098694A1 (en) * 2001-11-09 2010-04-22 Amgen Fremont Inc. Antibodies to cd40
US7338660B2 (en) 2001-11-09 2008-03-04 Abgenix, Inc. Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
US7618633B2 (en) 2001-11-09 2009-11-17 Amgen Fremont Inc. Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses
US7288251B2 (en) 2001-11-09 2007-10-30 Abgenix, Inc. Antibodies to CD40
US20070190051A1 (en) * 2001-11-09 2007-08-16 Abgenix, Inc. Antibodies to CD40
US8388971B2 (en) 2001-11-09 2013-03-05 Amgen Fremont Inc. Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses
US7626012B2 (en) 2001-11-09 2009-12-01 Amgen Fremont Inc. Nucleic acid molecules which encode antibodies that bind CD40
US20030211100A1 (en) * 2001-11-09 2003-11-13 Vahe Bedian Antibodies to CD40
US20090130715A1 (en) * 2001-11-09 2009-05-21 Abgenix, Inc. Antibodies to CD40
US20060093600A1 (en) * 2001-11-09 2006-05-04 Abgenix, Inc. Antibodies to CD40
EP2343086A2 (en) 2001-11-09 2011-07-13 Pfizer Products Inc. Antibodies to CD40
US20100209435A1 (en) * 2002-04-05 2010-08-19 Amgen Inc. Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
EP2314316A1 (en) 2002-04-05 2011-04-27 Amgen, Inc Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US8367063B2 (en) 2002-04-05 2013-02-05 Amgen, Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US8455629B2 (en) 2002-04-05 2013-06-04 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US20040023313A1 (en) * 2002-04-05 2004-02-05 Boyle William J Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US20110052604A1 (en) * 2002-04-05 2011-03-03 Amgen, Inc. Human Anti-OPGL Neutralizing Antibodies as Selective OPGL Pathway Inhibitors
EP2316922A1 (en) 2002-05-24 2011-05-04 Schering Corporation Neutralizing human anti-IGFR antibody
EP2316921A1 (en) 2002-05-24 2011-05-04 Schering Corporation Neutralizing human anti-IGFR antibody
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20060239968A1 (en) * 2002-08-30 2006-10-26 Wadih Arap Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
EP2277543A1 (en) 2002-09-06 2011-01-26 Amgen, Inc Therapeutic anti-IL-1R1 monoclonal antibody
EP2213685A1 (en) 2002-09-06 2010-08-04 Amgen Inc. Therapeutic anti-IL-1R1 monoclonal antibody
EP3020414A1 (en) 2002-09-06 2016-05-18 Amgen, Inc Therapeutic anti-il-1r1 monoclonal antibody
US20090252746A1 (en) * 2002-10-14 2009-10-08 Abbott Laboratories Erythropoietin receptor binding antibodies
EP2298811A2 (en) 2002-10-16 2011-03-23 Amgen Inc. Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors
WO2004050683A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
EP3000886A1 (en) 2003-03-19 2016-03-30 Amgen Fremont Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
WO2004084823A2 (en) 2003-03-19 2004-10-07 Abgenix, Inc. Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
EP3011971A1 (en) 2003-06-27 2016-04-27 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US8192985B2 (en) 2003-06-27 2012-06-05 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US7951588B2 (en) 2003-06-27 2011-05-31 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US7244616B2 (en) * 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
EP2338911A1 (en) 2003-06-27 2011-06-29 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
WO2005010046A1 (en) 2003-06-27 2005-02-03 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
EP3679951A1 (en) 2003-06-27 2020-07-15 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US8772027B2 (en) 2003-06-27 2014-07-08 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US9284591B2 (en) 2003-06-27 2016-03-15 Bayer Healthcare Llc Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US8409857B1 (en) 2003-06-27 2013-04-02 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
EP2808341A1 (en) 2003-06-27 2014-12-03 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
EP2457587A1 (en) 2003-06-27 2012-05-30 Amgen Fremont Inc. Anitbodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US8765466B2 (en) 2003-06-27 2014-07-01 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
EP2457586A1 (en) 2003-06-27 2012-05-30 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
EP3037105A1 (en) 2003-06-27 2016-06-29 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US20050048608A1 (en) * 2003-06-27 2005-03-03 Bayer Aktiengesellschaft Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
EP2341067A1 (en) 2003-07-18 2011-07-06 Amgen, Inc Specific binding agents to hepatocyte growth factor
US8821869B2 (en) 2003-08-04 2014-09-02 Amgen Fremont Inc. Treatment methods using c-Met antibodies
US7498420B2 (en) 2003-08-04 2009-03-03 Amgen Fremont Inc. Antibodies to c-Met
US20050054019A1 (en) * 2003-08-04 2005-03-10 Michaud Neil R. Antibodies to c-Met
US8163280B2 (en) 2003-08-04 2012-04-24 Amgen Fremont Inc. Antibodies to c-Met
US20100040629A1 (en) * 2003-08-04 2010-02-18 Abgenix, Inc. Antibodies to c-Met
US8562985B2 (en) 2003-08-04 2013-10-22 Amgen Fremont Inc. Antibodies to c-Met
WO2005016111A2 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
US8188249B2 (en) 2003-09-10 2012-05-29 Amgen Fremont Inc. Nucleic acid molecules encoding antibodies to M-CSF
US10280219B2 (en) 2003-09-10 2019-05-07 Amgen Fremont Inc. Antibodies to M-CSF
US7326414B2 (en) 2003-09-10 2008-02-05 Warner-Lambert Company Llc Antibodies to M-CSF
US9718883B2 (en) 2003-09-10 2017-08-01 Amgen Fremont Inc. Antibodies to M-CSF
EP3170840A1 (en) 2003-09-10 2017-05-24 Warner-Lambert Company LLC Antibodies to m-csf
US20080254032A1 (en) * 2003-09-10 2008-10-16 Abgenix, Inc. Antibodies to M-CSF
US20100247545A1 (en) * 2003-09-10 2010-09-30 Amgen Fremont Inc. Antibodies to m-csf
US7592430B2 (en) 2003-09-10 2009-09-22 Amgen Fremont Antibodies to M-CSF
US20050059113A1 (en) * 2003-09-10 2005-03-17 Vahe Bedian Antibodies to M-CSF
US7728113B2 (en) 2003-09-10 2010-06-01 Amgen Fremont Inc. Methods of treating arthritic conditions with antibodies to M-CSF
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US20110059041A1 (en) * 2003-09-12 2011-03-10 Alemseged Truneh Vaccine for treatment and prevention of herpes simplex virus infection
US7932372B2 (en) 2004-01-09 2011-04-26 Amgen Fremont Inc. Antibodies to MAdCAM
US20080124339A1 (en) * 2004-01-09 2008-05-29 Nicholas Pullen Antibodies to MAdCAM
US20050232917A1 (en) * 2004-01-09 2005-10-20 Nicholas Pullen Antibodies to MAdCAM
US9328169B2 (en) 2004-01-09 2016-05-03 Pfizer Inc. Human antibodies that bind human MAdCAM
US10259872B2 (en) 2004-01-09 2019-04-16 Pfizer, Inc. Antibodies to MAdCAM
US20070166308A1 (en) * 2004-01-09 2007-07-19 Nicholas Pullen Antibodies to MAdCAM
USRE45847E1 (en) 2004-01-09 2016-01-19 Pfizer Inc. Antibodies to MAdCAM
EP2418224A2 (en) 2004-03-19 2012-02-15 Amgen Inc. Reducing the risk of human and anti-human antibodies through V gene manipulation
WO2005092926A2 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
US20060002929A1 (en) * 2004-03-23 2006-01-05 Khare Sanjay D Monoclonal antibodies
EP2322215A2 (en) 2004-07-16 2011-05-18 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
EP2335727A2 (en) 2004-07-16 2011-06-22 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
US20060018910A1 (en) * 2004-07-16 2006-01-26 Pfizer Inc Combination treatment for non-hematologic malignancies
US7618626B2 (en) 2004-07-16 2009-11-17 Pfizer Inc Combination treatment for non-hematologic malignancies
US20110014207A1 (en) * 2004-07-16 2011-01-20 Pfizer Inc. Combination treatment for non-hematologic malignancies
EP2322217A2 (en) 2004-07-16 2011-05-18 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
EP2476427A2 (en) 2004-08-02 2012-07-18 Zenyth Operations PTY. Ltd. A method of treating cancer comprising a VEGF-B antagonist
EP2336177A1 (en) 2004-08-04 2011-06-22 Amgen, Inc Antibodies to DKK-1
WO2006052975A2 (en) 2004-11-08 2006-05-18 Schering Corporation Tumor association of mdl-1 and methods
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
WO2006068975A2 (en) 2004-12-20 2006-06-29 Abgenix, Inc. Binding proteins specific for human matriptase
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
EP3699191A1 (en) 2004-12-21 2020-08-26 MedImmune Limited Antibodies directed to angiopoietin-2 and uses thereof
EP2361933A2 (en) 2005-01-26 2011-08-31 Amgen Fremont Inc. Antibodies against interleukin-1 beta
EP2620450A2 (en) 2005-03-08 2013-07-31 Pharmacia & Upjohn Company LLC Anti-CTLA-4 antibody compositions
EP2311491A1 (en) 2005-03-08 2011-04-20 Pharmacia & Upjohn Company LLC Composition comprising an antibody against macrophage colony-stimulating factor (M-CSF) and a chelating agent
US7807159B2 (en) 2005-04-25 2010-10-05 Amgen Fremont Inc. Antibodies to myostatin
EP2295466A2 (en) 2005-04-25 2011-03-16 Pfizer Inc. Antibodies to myostatin
US20110091455A1 (en) * 2005-04-25 2011-04-21 Amgen Fremont Inc. Antibodies to myostatin
US20060263354A1 (en) * 2005-04-25 2006-11-23 Amgen Fremont Inc. Antibodies to myostatin
EP2444421A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
EP2444419A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
EP2444420A1 (en) 2005-04-26 2012-04-25 Pfizer Inc. P-Cadherin antibodies
EP2397498A2 (en) 2005-07-18 2011-12-21 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
EP2388277A2 (en) 2005-07-18 2011-11-23 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
US7868140B2 (en) 2005-07-18 2011-01-11 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
US8981071B2 (en) 2005-07-18 2015-03-17 Amgen, Inc. Human anti-B7RP1 neutralizing antibodies
EP2397499A2 (en) 2005-07-18 2011-12-21 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
US9266945B2 (en) 2005-07-18 2016-02-23 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
US10072090B2 (en) 2005-07-18 2018-09-11 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
US20080166352A1 (en) * 2005-07-18 2008-07-10 Amgen Inc. Human anti-B7RP1 Neutralizing Antibodies
EP2388276A2 (en) 2005-07-18 2011-11-23 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
EP2397497A2 (en) 2005-07-18 2011-12-21 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
EP2397496A2 (en) 2005-07-18 2011-12-21 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
US20110104757A1 (en) * 2005-07-18 2011-05-05 Amgen Inc. Human anti-B7RP1 Neutralizing Antibodies
US8642330B2 (en) 2005-08-08 2014-02-04 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US20100068135A1 (en) * 2005-08-08 2010-03-18 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
EP2960253A1 (en) 2005-09-07 2015-12-30 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
EP2447283A2 (en) 2005-09-07 2012-05-02 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1 (ALK-1)
US20070065444A1 (en) * 2005-09-07 2007-03-22 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
US8080646B2 (en) 2005-09-07 2011-12-20 Amgen Fremont, Inc. Human monoclonal antibodies to activin receptor-like kinase-1
US7537762B2 (en) 2005-09-07 2009-05-26 Amgen Fremont, Inc. Human monoclonal antibodies to activin receptor-like kinase-1
EP3381945A1 (en) 2005-09-07 2018-10-03 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
US9221915B2 (en) 2005-09-07 2015-12-29 Pfizer Inc. Human monoclonal antibodies to activin receptor-like kinase-1
WO2007059082A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
EP2548583A2 (en) 2005-11-10 2013-01-23 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
EP2366715A2 (en) 2005-11-14 2011-09-21 Amgen Inc. Rankl Antibody-PTH/PTHRP Chimeric Molecules
EP2816060A1 (en) 2005-11-14 2014-12-24 Amgen Inc. Rankl antibody-PTH/PTHRP chimeric molecules
EP2404616A2 (en) 2005-12-13 2012-01-11 AstraZeneca AB Binding proteins specific for insulin-like growth factors and uses thereof
EP2518083A2 (en) 2005-12-15 2012-10-31 Medimmune Limited Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLTL antagonist for treating cancer
WO2007068895A1 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
US8771695B2 (en) 2005-12-30 2014-07-08 U3 Pharma Gmbh Antibodies directed to HER-3 and uses thereof
US9988462B2 (en) 2005-12-30 2018-06-05 Daiichi Sankyo Europe Gmbh Material and methods for treating or preventing HER-3 associated diseases
EP2993187A2 (en) 2005-12-30 2016-03-09 U3 Pharma GmbH Antibodies directed to her-3 and uses thereof
WO2007077028A2 (en) 2005-12-30 2007-07-12 U3 Pharma Ag Antibodies directed to her-3 and uses thereof
US20080124345A1 (en) * 2005-12-30 2008-05-29 Mike Rothe Antibodies directed to HER-3 and uses thereof
US7705130B2 (en) 2005-12-30 2010-04-27 U3 Pharma Gmbh Antibodies directed to HER-3 and uses thereof
EP3196213A2 (en) 2005-12-30 2017-07-26 Daiichi Sankyo Europe GmbH Antibodies directed to her-3 and uses thereof
EP3950715A1 (en) 2005-12-30 2022-02-09 Amgen Inc. Antibodies directed to her-3 and uses thereof
US8071323B2 (en) 2006-04-07 2011-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies that bind human insulin like growth factors and their use
US9926367B2 (en) 2006-04-07 2018-03-27 Aerpio Therapeutics, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US20100055033A1 (en) * 2006-04-07 2010-03-04 The Government Of The United States Of America As Represented By The Secretary Antibody compositions and methods for treatment of neoplastic disease
EP3252079A1 (en) 2006-04-07 2017-12-06 Aerpio Therapeutics, Inc. Antibodies that bind human protein tyrosine phosphatase beta (hptp-ss) and uses thereof
EP2371865A2 (en) 2006-04-07 2011-10-05 Warner Chilcott Company, LLC Antibodies that bind human protein tyrosine phosphatase beta (HPTP-ß) and uses thereof
US11814425B2 (en) 2006-04-07 2023-11-14 Eye Point Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
EP2357202A1 (en) 2006-04-10 2011-08-17 AstraZeneca AB Targeted binding agents directed to Upar and uses thereof
EP2574624A1 (en) 2006-04-20 2013-04-03 Amgen Inc. GLP-1 compounds
EP2573111A1 (en) 2006-04-20 2013-03-27 Amgen Inc. GLP-1 compounds
US20080009607A1 (en) * 2006-05-22 2008-01-10 California Institute Of Technology Antibodies to sulfated carbohydrates
US8912011B2 (en) 2006-05-22 2014-12-16 California Institute Of Technology Antibodies to sulfated carbohydrates
US7745584B2 (en) 2006-05-22 2010-06-29 California Institute Of Technology Antibodies to sulfated carbohydrates
US20100071080A1 (en) * 2006-05-22 2010-03-18 Tully Sarah E Antibodies to sulfated carbohydrates
EP2420513A1 (en) 2006-08-03 2012-02-22 MedImmune Limited Targeted binding agents directed to PDGFR-alpha and uses thereof
EP2420514A1 (en) 2006-08-03 2012-02-22 MedImmune Limited Targeted binding agents directed to PDGFR-alpha and uses thereof
EP2511301A2 (en) 2006-08-04 2012-10-17 Medimmune Limited Human antibodies to ERBB2
WO2008017126A1 (en) 2006-08-11 2008-02-14 Csl Limited Treatment of pulmonary disease conditions
EP2526959A1 (en) 2006-08-11 2012-11-28 CSL Limited Treatment of pulmonary disease conditions
WO2008073300A2 (en) 2006-12-08 2008-06-19 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
EP3330292A1 (en) 2007-08-21 2018-06-06 Amgen, Inc Human c-fms antigen binding proteins
EP2592093A1 (en) 2007-08-21 2013-05-15 Amgen, Inc Human c-fms antigen binding proteins
EP2589610A1 (en) 2007-08-21 2013-05-08 Amgen, Inc Human c-fms antigen binding proteins
EP3666797A1 (en) 2007-08-23 2020-06-17 Amgen, Inc Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
EP4248976A2 (en) 2007-08-23 2023-09-27 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
DE202008018562U1 (en) 2007-08-23 2015-11-02 Amgen Inc. Antigen-binding Proteins Against Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9)
EP2236519A1 (en) 2007-09-18 2010-10-06 Amgen, Inc Human GM-CSF antigen binding proteins
US8828382B2 (en) 2007-09-26 2014-09-09 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor binding proteins
US20110110956A1 (en) * 2007-09-26 2011-05-12 Amgen, Inc. Heparin-Binding Epidermal Growth Factor-like Growth Factor Binding Proteins
EP2497783A2 (en) 2007-09-26 2012-09-12 U3 Pharma GmbH Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
WO2009040134A1 (en) 2007-09-26 2009-04-02 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
WO2009052588A1 (en) 2007-10-26 2009-04-30 Csl Limited Cytokine muteins
EP3211011A1 (en) 2007-11-16 2017-08-30 Nuvelo, Inc. Antibodies to lrp6
WO2009064944A2 (en) 2007-11-16 2009-05-22 Nuvelo, Inc. Antibodies to lrp6
US8912149B1 (en) 2007-11-28 2014-12-16 California Institute Of Technology Glycosaminoglycan mimetics
EP3239178A1 (en) 2007-12-14 2017-11-01 Bristol-Myers Squibb Company Binding molecules to the human ox40 receptor
EP2851374A1 (en) 2007-12-14 2015-03-25 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
EP2594590A1 (en) 2007-12-14 2013-05-22 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
EP2927244A1 (en) 2008-09-19 2015-10-07 MedImmune, LLC Antibodies directed to DLL4 and uses thereof
WO2010067308A2 (en) 2008-12-08 2010-06-17 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2865689A1 (en) 2008-12-08 2015-04-29 Compugen Ltd. FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP3184546A1 (en) 2008-12-23 2017-06-28 Amgen, Inc Human cgrp receptor binding proteins
EP3569620A1 (en) 2008-12-23 2019-11-20 Amgen Inc. Human cgrp receptor binding antibodies
WO2010075238A1 (en) 2008-12-23 2010-07-01 Amgen Inc. Human cgrp receptor binding proteins
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
EP3199551A2 (en) 2009-07-31 2017-08-02 E. R. Squibb & Sons, L.L.C. Fully human antibodies to btla
WO2011014438A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
WO2011017294A1 (en) 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
WO2011032204A1 (en) 2009-09-15 2011-03-24 Csl Limited Treatment of neurological conditions
WO2011049758A1 (en) 2009-10-09 2011-04-28 Amgen Inc. Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
EP3028717A1 (en) 2009-10-09 2016-06-08 Amgen, Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
US9487580B2 (en) 2009-10-26 2016-11-08 Amgen Inc. Human IL-23 antigen binding proteins
US8722033B2 (en) 2009-10-26 2014-05-13 Amgen Inc. Human IL-23 antigen binding proteins
EP3181586A1 (en) 2009-10-26 2017-06-21 Amgen, Inc Human il-23 antigen binding proteins
WO2011056600A1 (en) 2009-10-26 2011-05-12 Amgen Inc. Human il-23 antigen binding proteins
US9951129B2 (en) 2009-10-26 2018-04-24 Amgen Inc. Human IL-23 antigen binding proteins
EP3656790A1 (en) 2009-10-26 2020-05-27 Amgen, Inc Human il-23 antigen binding proteins
EP2719708A2 (en) 2009-11-13 2014-04-16 U3 Pharma GmbH Material and methods for treating or preventing HER-3 associated diseases
EP3351558A2 (en) 2009-11-13 2018-07-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing her-3 associated diseases
US9101760B2 (en) 2009-11-13 2015-08-11 U3 Pharma Gmbh Material and methods for treating or preventing HER-3 associated diseases
EP2896632A2 (en) 2009-11-13 2015-07-22 U3 Pharma GmbH Material and methods for treating or preventing HER-3 associated diseases
US9803025B2 (en) 2009-11-13 2017-10-31 Amgen, Inc. Material and methods for treating or preventing HER-3 associated diseases
US20110229406A1 (en) * 2009-11-13 2011-09-22 U3 Pharma Gmbh Material and methods for treating or preventing HER-3 associated diseases
WO2011060206A2 (en) 2009-11-13 2011-05-19 U3 Pharma Gmbh Material and methods for treating or preventing her-3 associated diseases
EP3670539A1 (en) 2009-11-13 2020-06-24 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing her-3 associated diseases
EP3279215A1 (en) 2009-11-24 2018-02-07 MedImmune Limited Targeted binding agents against b7-h1
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
WO2011071783A1 (en) 2009-12-07 2011-06-16 Amgen Inc. Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
EP3760642A1 (en) 2009-12-07 2021-01-06 Amgen Inc. Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
EP2711375A1 (en) 2009-12-07 2014-03-26 Amgen Inc. Human Antigen Binding Proteins that bind Beta-Klotho, FGF Receptors and complexes thereof
EP3202787A1 (en) 2009-12-07 2017-08-09 Amgen, Inc Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
EP2374816A1 (en) 2010-04-07 2011-10-12 Humalys Binding molecules against Chikungunya virus and uses thereof
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
US9738704B2 (en) 2010-04-07 2017-08-22 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
EP3670534A2 (en) 2010-04-15 2020-06-24 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
WO2012018404A2 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
WO2012035518A1 (en) 2010-09-17 2012-03-22 Compugen Ltd. Compositions and methods for treatment of drug resistant multiple myeloma
WO2012058393A2 (en) 2010-10-27 2012-05-03 Amgen Inc. Dkk1 antibodies and methods of use
US10800839B2 (en) 2010-10-27 2020-10-13 Amgen Inc. DKK1 antibodies and methods of use
EP3838922A1 (en) 2010-10-27 2021-06-23 Amgen Inc. Dkk1 antibodies and methods of use
EP3219725A2 (en) 2010-10-27 2017-09-20 Amgen, Inc Dkk1 antibodies and methods of use
WO2012102679A1 (en) 2011-01-24 2012-08-02 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
EP3763388A1 (en) 2011-02-18 2021-01-13 AbbVie Stemcentrx LLC Novel modulators and methods of use
WO2012118903A2 (en) 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
WO2012138997A1 (en) 2011-04-07 2012-10-11 Amgen Inc. Novel egfr binding proteins
US9676846B2 (en) 2011-04-12 2017-06-13 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
WO2012154999A1 (en) 2011-05-10 2012-11-15 Amgen Inc. Methods of treating or preventing cholesterol related disorders
EP3597218A1 (en) 2011-05-10 2020-01-22 Amgen, Inc Methods of treating or preventing cholesterol related disorders
US11248052B2 (en) 2011-06-06 2022-02-15 Amgen Inc. Antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP3447074A2 (en) 2011-06-06 2019-02-27 Amgen, Inc Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells
WO2013012855A1 (en) 2011-07-18 2013-01-24 Amgen Inc. Apelin antigen-binding proteins and uses thereof
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US10815300B2 (en) 2011-10-13 2020-10-27 Aerpio Pharmaceuticals, Inc. Methods for treating vascular leak syndrome and cancer
EP3501536A1 (en) 2011-10-13 2019-06-26 Aerpio Therapeutics, Inc. Treatment of ocular disease
WO2013056233A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Treatment of ocular disease
US10329357B2 (en) 2011-10-13 2019-06-25 Aerpio Therapeutics, Inc. Treatment of ocular disease
US10150811B2 (en) 2011-10-13 2018-12-11 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
WO2013068902A1 (en) 2011-11-08 2013-05-16 Pfizer Inc. Methods of treating inflammatory disorders using anti-m-csf antibodies
WO2013075048A1 (en) 2011-11-16 2013-05-23 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
US9409976B2 (en) 2012-02-08 2016-08-09 Igm Biosciences, Inc. CDIM binding proteins and uses thereof
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
WO2013120012A2 (en) 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
EP3929208A1 (en) 2012-04-27 2021-12-29 Amgen Inc. Human cd30 ligand antigen binding proteins
EP3431492A1 (en) 2012-04-27 2019-01-23 Novo Nordisk A/S Human cd30 ligand antigen binding proteins
WO2013163377A1 (en) 2012-04-27 2013-10-31 Novo Nordisk A/S Human cd30 ligand antigen binding proteins
EP4230641A2 (en) 2012-04-27 2023-08-23 Amgen Inc. Human cd30 ligand antigen binding proteins
EP3656399A1 (en) 2012-05-03 2020-05-27 Amgen, Inc Stable formulations containing anti-pcsk9 antibodies
WO2013166448A1 (en) 2012-05-03 2013-11-07 Amgen Inc. Stable formulations containing anti-pcsk9 antibodies
EP3498857A1 (en) 2012-06-11 2019-06-19 Amgen, Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
EP3540070A1 (en) 2012-06-11 2019-09-18 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
WO2013188448A2 (en) 2012-06-11 2013-12-19 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
WO2013186719A1 (en) 2012-06-15 2013-12-19 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
US9751937B2 (en) 2012-06-15 2017-09-05 Pfizer Inc. Antagonist antibodies against GDF-8 and uses therefor
US8992913B2 (en) 2012-06-15 2015-03-31 Pfizer Inc. Antagonist antibodies against GDF-8 and uses therefor
WO2014089335A2 (en) 2012-12-07 2014-06-12 Amgen Inc. Bcma antigen binding proteins
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
WO2014087299A1 (en) 2012-12-07 2014-06-12 Pfizer Inc. Engineered monomeric antibody fragments
EP3783030A1 (en) 2012-12-21 2021-02-24 Merck Sharp & Dohme Corp. Antibodies that bind to human programmed death ligand 1 (pd-l1)
WO2014100079A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Antibodies that bind to human programmed death ligand 1 (pd-l1)
WO2014130879A2 (en) 2013-02-22 2014-08-28 Stem Centrx, Inc. Novel antibody conjugates and uses thereof
EP3556400A1 (en) 2013-02-22 2019-10-23 AbbVie Stemcentrx LLC Method of making antidll3-antibody pbd conjugates
US11492417B2 (en) 2013-03-13 2022-11-08 Amgen Inc. Proteins specific for BAFF and B7RP1 and uses thereof
US10421823B2 (en) 2013-03-13 2019-09-24 Amgen Inc. Proteins specific for BAFF and B7RP1 and uses thereof
US10421824B2 (en) 2013-03-13 2019-09-24 Amgen Inc. Proteins specific for BAFF and B7RP1
WO2014159764A1 (en) 2013-03-14 2014-10-02 Amgen Inc. Chrdl-1 antigen binding proteins and methods of treatment
WO2014144632A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Human pac1 antibodies
WO2014144553A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
EP3683237A1 (en) 2013-03-15 2020-07-22 Amgen Inc. Human pac1 antibodies
WO2014165422A1 (en) 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2014182970A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
WO2014209384A1 (en) 2013-06-28 2014-12-31 Amgen Inc. Methods for treating homozygous familial hypercholesterolema
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
US9464139B2 (en) 2013-08-30 2016-10-11 Amgen Inc. GITR antigen binding proteins and methods of use thereof
EP3427751A1 (en) 2013-08-30 2019-01-16 Amgen, Inc Gitr antigen binding proteins
WO2015173756A2 (en) 2014-05-16 2015-11-19 Pfizer Inc. Bispecific antibodies
EP3834842A1 (en) 2014-08-19 2021-06-16 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
WO2016028672A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
WO2016028656A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-tigit antibodies
EP3575316A1 (en) 2014-08-27 2019-12-04 Amgen, Inc Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
US11149078B2 (en) 2014-08-27 2021-10-19 Amgen Inc. Variants of tissue inhibitor or metalloprotienase type three (TIMP-3), compositions and methods
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
WO2016042412A1 (en) 2014-09-16 2016-03-24 Symphogen A/S Anti-met antibodies and compositions
WO2016171742A1 (en) 2015-04-24 2016-10-27 Amgen Inc. Methods for treating or preventing migraine headache
EP3653225A1 (en) 2015-04-24 2020-05-20 Amgen, Inc Methods for treating or preventing migraine headache using antibodies directed at the cgrp receptor
EP4105235A1 (en) 2015-10-02 2022-12-21 Symphogen A/S Anti-pd-1 antibodies and compositions
WO2017075124A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Antibody neutralizing human respiratory syncytial virus
WO2017079273A2 (en) 2015-11-03 2017-05-11 Glycomimetics, Inc. Antibodies for targeting cancer stem cells and treating aggressive cancers
WO2017079215A1 (en) 2015-11-03 2017-05-11 Glycomimetics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
US10294303B2 (en) 2015-12-23 2019-05-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
US11046774B2 (en) 2015-12-23 2021-06-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
EP3978531A1 (en) 2016-04-12 2022-04-06 Symphogen A/S Anti-tim-3 antibodies and compositions
US11453717B2 (en) 2016-04-29 2022-09-27 Joint Stock Company “Biocad” Trispecific antibodies against IL-17A, IL-17F and other pro-inflammatory molecule
WO2018058022A1 (en) 2016-09-26 2018-03-29 Merck Sharp & Dohme Corp. Anti-cd27 antibodies
WO2018069500A2 (en) 2016-10-13 2018-04-19 Symphogen A/S Anti-lag-3 antibodies and compositions
US11352443B2 (en) 2016-11-09 2022-06-07 North Carolina State University Treatment of allergic diseases with chimeric protein
WO2018091661A1 (en) 2016-11-18 2018-05-24 Symphogen A/S Anti-pd-1 antibodies and compositions
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
US10905772B2 (en) 2017-01-17 2021-02-02 Amgen Inc. Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)
WO2018185232A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-1, tim-3, and lag-3
EP4116328A1 (en) 2017-04-05 2023-01-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combination therapies targeting pd-1, tim-3, and lag-3
EP4230654A1 (en) 2017-04-05 2023-08-23 Symphogen A/S Combination therapies targeting pd-1, tim-3, and lag-3
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
US10851164B2 (en) 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
WO2018194496A2 (en) 2017-04-17 2018-10-25 Закрытое Акционерное Общество "Биокад" Monoclonal antibody to pd-l1
WO2018222770A1 (en) 2017-05-31 2018-12-06 Amgen Inc. Anti-jagged1 antigen binding proteins
US11897965B2 (en) 2017-05-31 2024-02-13 Amgen Inc. Anti-Jagged1 antigen binding proteins
US11897963B2 (en) 2017-05-31 2024-02-13 Amgen Inc. Anti-Jagged1 antigen binding proteins
US11028180B2 (en) 2017-05-31 2021-06-08 Amgen Inc. Anti-Jagged1 antigen binding proteins
WO2018237097A1 (en) 2017-06-20 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
US11802156B2 (en) 2017-07-14 2023-10-31 Pfizer Inc. Antibodies to MAdCAM
WO2019014572A1 (en) 2017-07-14 2019-01-17 Pfizer, Inc. Antibodies to madcam
WO2019028382A1 (en) 2017-08-04 2019-02-07 Amgen Inc. Method of conjugation of cys-mabs
WO2019070164A1 (en) 2017-10-03 2019-04-11 Закрытое Акционерное Общество "Биокад" MONOCLONAL ANTIBODY TO IL-5Rα
US11840567B2 (en) 2017-10-03 2023-12-12 Joint Stock Company “Biocad” Bispecific antibodies with specific binding to CD47 and PD-L1
WO2019108806A1 (en) 2017-11-29 2019-06-06 Board Of Regents Of The University Of Texas System Compositions and methods for cancer therapy
WO2019147831A1 (en) 2018-01-26 2019-08-01 Regeneron Pharmaceuticals, Inc. Anti-tmprss2 antibodies and antigen-binding fragments
WO2019152642A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2019190931A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Anti-pfrh5 antibodies and antigen-binding fragments thereof
WO2020018503A2 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
WO2020055293A1 (en) 2018-09-14 2020-03-19 Закрытое Акционерное Общество "Биокад" Pacas9 nuclease
WO2020091634A1 (en) 2018-10-31 2020-05-07 Закрытое Акционерное Общество "Биокад" Monoclonal antibody that specifically binds to cd20
US11629195B2 (en) 2019-02-01 2023-04-18 Regeneron Pharmaceuticals, Inc. Anti-IL2 receptor gamma antigen-binding proteins
WO2020160242A1 (en) 2019-02-01 2020-08-06 Regeneron Pharmaceuticals, Inc. Anti-il2 receptor gamma antigen-binding proteins
WO2020198009A1 (en) 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. EGFR x CD28 MULTISPECIFIC ANTIBODIES
WO2020218951A2 (en) 2019-04-23 2020-10-29 Закрытое Акционерное Общество "Биокад" Monoclonal antibody that binds specifically to gitr
WO2021001458A1 (en) 2019-07-01 2021-01-07 Tonix Pharma Holdings Limited Anti-cd154 antibodies and uses thereof
WO2021021676A1 (en) 2019-07-26 2021-02-04 Amgen Inc. Anti-il13 antigen binding proteins
WO2021044005A1 (en) 2019-09-06 2021-03-11 Symphogen A/S Anti-cd73 antibodies
WO2021054867A1 (en) 2019-09-19 2021-03-25 Закрытое Акционерное Общество "Биокад" IMMUNOCYTOKINE COMPRISING HETERODIMERIC PROTEIN COMPLEX BASED ON IL-15/IL-15Rα
WO2021091906A1 (en) 2019-11-04 2021-05-14 Amgen Inc. Methods for treating leukemia
WO2021113591A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Vegf mini-traps and methods of use thereof
WO2021163076A1 (en) 2020-02-10 2021-08-19 Regeneron Pharmaceuticals, Inc. ANTl-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
EP4209507A1 (en) 2020-04-02 2023-07-12 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
EP3889177A1 (en) 2020-04-02 2021-10-06 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021219871A2 (en) 2020-04-30 2021-11-04 Aduro Biotech Holdings, Europe B.V. Anti-cd103 antibodies
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
WO2021242815A1 (en) 2020-05-26 2021-12-02 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2022003530A1 (en) 2020-06-30 2022-01-06 Fondazione Toscana Life Sciences Neutralizing antibodies to sars coronavirus-2
IT202000015754A1 (en) 2020-06-30 2021-12-30 Fond Toscana Life Sciences ANTIBODIES TO CORONAVIRUS
WO2022020636A2 (en) 2020-07-24 2022-01-27 Amgen Inc. Immunogens derived from sars-cov2 spike protein
WO2022023292A2 (en) 2020-07-31 2022-02-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Corona virus spike protein-targeting antibodies and use thereof
WO2022175831A1 (en) 2021-02-16 2022-08-25 Fondazione Toscana Life Sciences Vaccines against sars-cov-2
IT202100003470A1 (en) 2021-02-16 2022-08-16 Fond Toscana Life Sciences VACCINES AGAINST SARS-COV-2
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
WO2023287875A1 (en) 2021-07-14 2023-01-19 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
WO2023155902A1 (en) 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
WO2023173132A1 (en) 2022-03-11 2023-09-14 Regeneron Pharmaceuticals, Inc. Anti-glp1r antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
WO2023180533A1 (en) 2022-03-25 2023-09-28 Les Laboratoires Servier Anti-gal3 antibodies and compositions
WO2024026470A2 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Anti-tfr:payload fusions and methods of use thereof
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024050526A1 (en) 2022-09-02 2024-03-07 Biomarin Pharmaceutical Inc. Compositions and methods for treating long qt syndrome

Also Published As

Publication number Publication date
WO1988003558A1 (en) 1988-05-19
AU1100288A (en) 1988-06-01
CA1297436C (en) 1992-03-17
ES2013324A6 (en) 1990-05-01
EP0289597B1 (en) 1994-02-02
KR890700164A (en) 1989-03-10
JPH01501363A (en) 1989-05-18
DE3789017D1 (en) 1994-03-17
EP0289597A4 (en) 1990-03-27
EP0289597A1 (en) 1988-11-09

Similar Documents

Publication Publication Date Title
US4912040A (en) Eucaryotic expression system
US5595886A (en) Protein complexes having Factor VIII:C activity and production thereof
Pannekoek et al. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family.
CA1341208C (en) Proteins with factor viii activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US5112950A (en) Factor viii analog, preparation process, and pharmaceutical composition containing it
US5451521A (en) Procoagulant proteins
Voorberg et al. Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids.
CA2368797C (en) Cell culture process
US5422260A (en) Human factor VIII:c muteins
AU645539B2 (en) A recombinant human factor VIII derivative
Pittman et al. Role of the B domain for factor VIII and factor V expression and function
EP0500734B1 (en) Protein complexes having factor viii:c activity and production thereof
JPH0788399B2 (en) Novel procoagulant protein
Grinnell et al. Trans–Activated Expression of Fully Gamma–Carboxylated Recombinant Human Protein C, an Antithrombotic Factor
EP0297066B1 (en) Novel fibrinolytic enzymes
CA2093575A1 (en) Human antithrombin iii mutant
EP0394261A1 (en) Novel thrombolytic proteins
EP0275856A1 (en) New plasminogen activators
EP0480923B1 (en) Method of producing proteins with fviii activity and/or fviii derivatives
Yamauchi et al. Production of human antithrombin-III in a serum-free culture of CHO cells
US5610033A (en) Method of producing proteins with FVIII activity and/or FVIII derivatives
JPH022338A (en) Simultaneous development in eucaryotic cell
AU632495B2 (en) Method of producing proteins with fviii activity and/or fviii derivatives
US20040235715A1 (en) Method of producing glycosylated bikunin
Asakura et al. Production of human antithrombin-III in a serum-free culture of CHO cells

Legal Events

Date Code Title Description
AS Assignment

Owner name: GENETICS INSTITUTE, INC., 87 CAMBRIDGEPARK DR., CA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:KAUFMAN, RANDAL J.;DORNER, ANDREW;REEL/FRAME:004691/0038

Effective date: 19870318

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAT HLDR NO LONGER CLAIMS SMALL ENT STAT AS INDIV INVENTOR (ORIGINAL EVENT CODE: LSM1); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 4

SULP Surcharge for late payment
FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: GENETICS INSTITUTE, LLC, MASSACHUSETTS

Free format text: CHANGE OF NAME;ASSIGNOR:GENETICS INSTITUTE, INC.;REEL/FRAME:012937/0815

Effective date: 20020101